Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Otorhinolaryngology

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 685 articles:
HTML format



Single Articles


    February 2025
  1. IQBAL MS, West N, Kovarik J, Jackson M, et al
    Effective, efficient palliative radiotherapy for advanced head and neck cancer: Real world data using 25 Gy in 5 fractions.
    Oral Oncol. 2025;162:107214.
    PubMed    


  2. KHAN A, Pillay M, Bipath R, Msimang M, et al
    Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?
    Oral Oncol. 2025;162:107208.
    PubMed     Abstract available


  3. MO Y, Wei Y, Liang L, Wu T, et al
    Clinical significance of post-chemoradiotherapy 2-[(18)F]FDG PET/CT response in locally advanced nasopharyngeal carcinoma: A real-world study.
    Oral Oncol. 2025;161:107160.
    PubMed     Abstract available


  4. LOUBIERES C, Baudouin R, Circiu M, Couineau F, et al
    Functional and oncological outcomes of transoral laser versus robotic surgery in supraglottic squamous cell carcinoma.
    Oral Oncol. 2025;161:107178.
    PubMed     Abstract available


  5. PERSHAD AR, Ferraro T, Shaver TB, Lee E, et al
    Pathologic responses and clinical outcomes with neoadjuvant doublet chemotherapy for newly diagnosed, surgically-resectable p16-positive oropharyngeal cancer.
    Oral Oncol. 2025;161:107139.
    PubMed     Abstract available


  6. FENG ZK, Wu WB, Zou RC, Zhang JZ, et al
    Postradiotherapy nasopharyngeal necrosis with granulation mass: Insights from a multicentre study.
    Oral Oncol. 2025;161:107170.
    PubMed     Abstract available


  7. LYU SI, Fretter C, Eckel HNC, Knipper K, et al
    High expression of H2AX/gamma-H2AX is associated with distinct biological pathway alterations and shorter survival in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;161:107171.
    PubMed     Abstract available


  8. KWON JJ, Milner TD, Kurten C, Pang EH, et al
    Towards transcervical ultrasound-guided transoral robotic surgery.
    Oral Oncol. 2025;161:107167.
    PubMed     Abstract available


    January 2025
  9. WENGER TA, Gao J, Nurimba M, Phung PG, et al
    Palliative care utilization among head and neck cancer patients: A population-based analysis.
    Oral Oncol. 2025;162:107205.
    PubMed     Abstract available


  10. CHEN L, Fang R, Cai Z, Huang B, et al
    CD271(high) cancer stem cells regulate macrophage polarization in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;162:107181.
    PubMed     Abstract available


  11. YIN Z, Zhao H, Zhu C, Fang J, et al
    Comment on: Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
    Oral Oncol. 2025;161:107195.
    PubMed    


  12. JIANG H, Zhou L, Zhao T, Zou G, et al
    Anaplastic thyroid carcinoma in a 43-year-old female confirmed by metastatic lymph node pathology: A case report.
    Oral Oncol. 2025;161:107192.
    PubMed    


  13. JIANG H, Zhou L, Zou G, Zhang H, et al
    Synchronous papillary and medullary thyroid carcinoma with distinct genetic mutations: A case report.
    Oral Oncol. 2025;161:107191.
    PubMed    


  14. LI MH, Hu YJ, Shan HM, Gao XL, et al
    The role of lymph node level ratio in predicting prognosis and the benefits of postoperative radiotherapy in patients with pathological N1 stage head and neck squamous cell carcinoma.
    Oral Oncol. 2025;161:107193.
    PubMed     Abstract available


  15. HUTTINGER ZM, Gogineni E, Baliga S, Blakaj DM, et al
    Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;161:107179.
    PubMed     Abstract available


  16. TOPKAN E, Somay E, Selek U
    Commentary on "Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF".
    Oral Oncol. 2025;161:107175.
    PubMed    


  17. SENYUREK S, Durankus NK, Selek U, Topkan E, et al
    Comment on "The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma".
    Oral Oncol. 2025;161:107177.
    PubMed    


  18. GIUNCO S, Del Mistro A, Morello M, Lidonnici J, et al
    From infection to immortality: The role of HPV and telomerase in head and neck cancer.
    Oral Oncol. 2025;161:107169.
    PubMed     Abstract available


  19. HANNA GJ, Zheng D, Gao W, Hair GM, et al
    PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.
    Oral Oncol. 2025;161:107146.
    PubMed     Abstract available


  20. XU S, He J, Liu Z, Pei Y, et al
    Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2025;161:107161.
    PubMed     Abstract available


    December 2024
  21. KAOREY N, Dickinson K, Agnihotram VR, Zeitouni A, et al
    The role of ctDNA from liquid biopsy in predicting survival outcomes in HPV-negative head and neck cancer: A meta-analysis.
    Oral Oncol. 2024;161:107148.
    PubMed     Abstract available


  22. LIU Y, Fu N, Liu H, Su S, et al
    Corrigendum to "Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations" [160 (2025) 107120/Article:OO_107120].
    Oral Oncol. 2024 Dec 30:107135. doi: 10.1016/j.oraloncology.2024.107135.
    PubMed    


  23. DIETRICH N, Watson E, Tadic T, Martino R, et al
    Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy.
    Oral Oncol. 2024;161:107132.
    PubMed     Abstract available


  24. FANG Q, Yuan J, Zhang X, Dai L, et al
    Omitting elective neck dissection in cT1/2N0 oral squamous cell carcinoma with sentinel lymph node metastasis: A prospective study.
    Oral Oncol. 2024;161:107149.
    PubMed     Abstract available


  25. PRICE JM, Garcez K, Hughes C, Lee LW, et al
    The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2024;161:107138.
    PubMed     Abstract available


  26. STRUCKMEIER AK, Gosau M, Smeets R
    Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma - A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA.
    Oral Oncol. 2024;161:107145.
    PubMed     Abstract available


  27. MEGWALU UC, Ma Y, Divi V
    Association of race and ethnicity with quality of care among head and neck cancer patients in California.
    Oral Oncol. 2024;161:107144.
    PubMed     Abstract available


  28. PACE GM, Costantino A, De Virgilio A
    Comment on "Surgical, functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal cancers: A systematic review".
    Oral Oncol. 2024;161:107142.
    PubMed    


  29. YU ST, Huang D, Xiong C, Xie R, et al
    Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports.
    Oral Oncol. 2024;161:107140.
    PubMed     Abstract available


  30. ALMEIDA ND, Yu H, Iovoli AJ, Fang M, et al
    Prophylactic gastrostomy tube during chemoradiation for head and neck cancer decreases weight loss but increases rate of tube use beyond six months.
    Oral Oncol. 2024;160:107136.
    PubMed     Abstract available


  31. DA MOTA SANTANA LA, Dos Santos Barreto M, Santos GA, Gopalsamy RG, et al
    Comment on "Time to treatment for head and neck cancer patients decreased during the early phase of the COVID-19 pandemic".
    Oral Oncol. 2024;160:107134.
    PubMed    


  32. PRACHA SH, Shrestha S, Ryan N, Upadhaya P, et al
    Targeting macrophage migration inhibitory factor to inhibit T cell immunosuppression in the tumor microenvironment and improve cancer outcomes in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;160:107126.
    PubMed     Abstract available


  33. LI H, Lou L, Du J, Li M, et al
    Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma.
    Oral Oncol. 2024;160:107129.
    PubMed     Abstract available


  34. SANKAR GANESH P, Naseef Pathoor N, Kanna Gopal R
    Letter to the editor regarding, "Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma".
    Oral Oncol. 2024;159:107091.
    PubMed     Abstract available


  35. BALAJI H, Aithal VU, Varghese JJ, Devaraja K, et al
    Agreement between patient-reported and clinician-rated speech and swallowing outcomes - Understanding the trend in post-operative oral cavity cancer patients.
    Oral Oncol. 2024;159:107068.
    PubMed     Abstract available


  36. BALAGURU L, Hanubal KS, Galochkina Z, Lee JH, et al
    Surgical and functional outcomes after salvage oropharyngectomy.
    Oral Oncol. 2024;159:107050.
    PubMed     Abstract available


  37. KORIC A, Chang CP, Hu S, Snyder J, et al
    Oral health-related quality of life among oropharyngeal cancer survivors.
    Oral Oncol. 2024;159:107062.
    PubMed     Abstract available


  38. BOZKURT G, Turri Zanoni M, Ferrari M, Ioppi A, et al
    Salvage surgery in nasopharyngeal Cancer: Unraveling the efficacy of transnasal endoscopic nasopharyngectomy for advanced stage recurrent tumors.
    Oral Oncol. 2024;159:107048.
    PubMed     Abstract available


  39. DANIELS KE, Awad DR, Liu SX, Mocharnuk J, et al
    Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;159:107031.
    PubMed     Abstract available


  40. GREEN L, McDowell L, Ip F, Tapia M, et al
    Early return to work is possible after transoral robotic surgery (TORS) in carefully selected patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;159:107032.
    PubMed     Abstract available


  41. LU YT, Lin CW, Su SC, Ho YT, et al
    L48H37, a curcumin analog, suppresses matrix metalloproteinase-9 expression and activity to hamper nasopharyngeal cancer cell migration.
    Oral Oncol. 2024;159:107038.
    PubMed     Abstract available


  42. STAIBANO P, Au M, Xie M, Gupta MK, et al
    Return to work and self-reported swallowing following transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma: A retrospective cohort study.
    Oral Oncol. 2024;159:107033.
    PubMed     Abstract available


  43. MORTAJA S, Chiumenti FA, Kalaskar DM, Dwivedi RC, et al
    Surgical complications and functional outcomes of 3191 jejunal free flaps used for reconstruction of circumferential defects following head and neck cancer resections: A systematic review.
    Oral Oncol. 2024;160:107130.
    PubMed     Abstract available


    November 2024
  44. MARRET G, Lamy C, Vacher S, Cabel L, et al
    Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA.
    Oral Oncol. 2024;160:107111.
    PubMed     Abstract available


  45. JEYARAJ G
    Letter to the editor, "Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.".
    Oral Oncol. 2024;160:107092.
    PubMed    


  46. LIU Y, Fu N, Liu H, Su S, et al
    Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
    Oral Oncol. 2024;160:107120.
    PubMed     Abstract available


  47. YAN C, Wang R, Zhang C, Lin G, et al
    Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF.
    Oral Oncol. 2024;160:107119.
    PubMed     Abstract available


  48. VON WITZLEBEN A, Grages A, Thomas J, Ezic J, et al
    Immune checkpoint expression on tumor-infiltrating lymphocytes (TIL) is dependent on HPV status in oropharyngeal carcinoma (OPSCC) - A single-cell RNA sequencing analysis.
    Oral Oncol. 2024;159:107107.
    PubMed     Abstract available


  49. LI S, Zhao T, Liu N, Li Y, et al
    Global research on oral cancer: A bibliometric analysis based on 82 highly cited publications from 2014 to 2024.
    Oral Oncol. 2024;159:107094.
    PubMed     Abstract available


  50. YANG B, Dai X, Li Z, Wu Z, et al
    Noninvasive surface-enhanced Raman spectroscopy outperforms combined positive score in predicting sensitivity to neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;159:107105.
    PubMed     Abstract available


  51. RENGASAMY G, Priya Veeraraghavan V
    Using salivary DNA methylation to predict aging, cell changes, and protein levels for assessing oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107086.
    PubMed    


  52. LEE YC, Hsin LJ, Lin WN, Fang TJ, et al
    Robot-assisted versus conventional neck dissection in head and neck cancers: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107101.
    PubMed     Abstract available


  53. MORGENTHALER J, Trommer M, Khor R, Wada M, et al
    Can we safely de-escalate HPV(+) oropharyngeal cancers? - A review of current practices and novel approaches.
    Oral Oncol. 2024;159:107089.
    PubMed     Abstract available


  54. LENNON SILVA CUNHA J
    In reply to "Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study".
    Oral Oncol. 2024;159:107096.
    PubMed    


  55. TOPKAN E, Somay E, Ozturk D, Selek U, et al
    Commentary on "Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions".
    Oral Oncol. 2024;159:107099.
    PubMed    


  56. SHANG K, Li T, Chen Y, Luo X, et al
    Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A single center prospective phase II clinical trial.
    Oral Oncol. 2024;159:107087.
    PubMed     Abstract available


  57. COSTANTINO A, Haughey B, Alamoudi U, Magnuson JS, et al
    Challenges in treating oropharyngeal cancer in the elderly: The role of transoral surgery.
    Oral Oncol. 2024;158:106996.
    PubMed    


  58. SOLARZ P, Mackiewicz-Nartowicz H, Sinkiewicz A, Burduk P, et al
    Results of CO2 laser surgery in laryngeal papillomatosis.
    Oral Oncol. 2024;158:107004.
    PubMed     Abstract available


  59. ASHIQUE S, Houshyari M, Islam A, Pal R, et al
    The role of microbiota in nasopharyngeal cancer: Where do we stand?
    Oral Oncol. 2024;158:106982.
    PubMed     Abstract available


  60. DE SENA COSTA DE OLIVEIRA D, Cunha JLS
    Comment on: Salivary DNA methylation derived estimates of biological aging, cellular frequency, and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107097.
    PubMed    


  61. HIMANI
    Letter to the editor: Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
    Oral Oncol. 2024;159:107093.
    PubMed    


    October 2024
  62. MUTHAMIZH S, Balachandran S, Dilipan E
    Opinion on "Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
    Oral Oncol. 2024;159:107095.
    PubMed    


  63. LEHYANTI J, Even C, Fessart E, Wagner-Ballon C, et al
    Management of oligometastatic head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2024;159:107085.
    PubMed     Abstract available


  64. VILLARME A, Ebran N, Pace-Loscos T, Schiappa R, et al
    Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2024;159:107082.
    PubMed     Abstract available


  65. KARAMCHANDANI S, Sahovaler A, Crosbie-Jones E, McGurk M, et al
    Incidence and predictive factors for positive non-sentinel lymph nodes in completion neck dissection following a positive sentinel node biopsy in early oral cancer.
    Oral Oncol. 2024;159:107081.
    PubMed    


  66. LI D, Lopez A, Shrivastava N, Chan W, et al
    Comprehensive functional evaluation of head and neck squamous cell carcinoma with BH3-profiling demonstrates apoptotic competency and therapeutic efficacy of BH3-mimetics.
    Oral Oncol. 2024;159:107069.
    PubMed     Abstract available


  67. WU WB, Xia L, Feng ZK, Liang JL, et al
    Characteristics and treatment of epistaxis in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107071.
    PubMed     Abstract available


  68. ZANG Y, Lu Y, Yu J, Dong Q, et al
    FOXP3 inhibits proliferation and migration by competitively inhibiting YAP1 in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107066.
    PubMed     Abstract available


  69. GARSET-ZAMANI M, Lomholt AF, Charabi BW, Norling R, et al
    Surgeon-performed intraoperative transoral ultrasound improves the detection of human papillomavirus-positive head and neck cancers of unknown primary.
    Oral Oncol. 2024;159:107073.
    PubMed     Abstract available


  70. LIU C, Zhao H, Lu Y, Xia Y, et al
    Nomograms to predict occult contralateral central lymph node metastases in unilateral papillary thyroid carcinoma with ipsilateral clinical lymph node metastasis.
    Oral Oncol. 2024;159:107051.
    PubMed     Abstract available


  71. SONG Y, Zhang Y, Bai Y, Wang T, et al
    Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center study.
    Oral Oncol. 2024;159:107067.
    PubMed     Abstract available


  72. AWEEDA M, Richard K, Arnaud EH, Divi V, et al
    Factors influencing lymph node yield in head and neck squamous cell carcinoma: A scoping review.
    Oral Oncol. 2024;159:107070.
    PubMed     Abstract available


  73. HE SQ, Liu GY, Yu YH, Wang L, et al
    Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.
    Oral Oncol. 2024;159:107074.
    PubMed     Abstract available


  74. LEE RH, Evans C, Alqasieer Y, Knott PD, et al
    Bite me: Can active biting during trismus therapy improve mouth opening in head and neck cancer patients?
    Oral Oncol. 2024;159:107064.
    PubMed    


  75. ZHAO BY, Hirayama S, Goss D, Zhao Y, et al
    Human papillomavirus-associated nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107057.
    PubMed     Abstract available


  76. TANG WZ, Xu WZ, Liu TH
    Exploring the potential of gemcitabine, capecitabine, and tislelizumab after anti-PD-1 treatment in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107065.
    PubMed    


  77. YACOUB I, Qian JY, Nashed K, Youssef M, et al
    Radiation techniques and advancements in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107060.
    PubMed    


  78. GAUDIOSO P, Contro G, Taboni S, Costantino P, et al
    Intraoperative surgical navigation as a precision medicine tool in sinonasal and craniofacial oncologic surgery.
    Oral Oncol. 2024;157:106979.
    PubMed     Abstract available


  79. DAWSON A, Karimi AH, Shaikh MH, Gazala W, et al
    Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2024;159:107061.
    PubMed     Abstract available


  80. AKASHANAND, Zahiruddin QS, Jena D, Ballal S, et al
    Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
    Oral Oncol. 2024;159:107063.
    PubMed     Abstract available


    September 2024
  81. LECHIEN JR
    Surgical, Functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
    Oral Oncol. 2024;159:107047.
    PubMed     Abstract available


  82. KEEFE K, McCrary HC, Wei M, Mark B, et al
    Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study.
    Oral Oncol. 2024;159:107041.
    PubMed     Abstract available


  83. DHARSHINI RAJATHIRAJAN S
    Commentary on "Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients".
    Oral Oncol. 2024;159:107053.
    PubMed    


  84. LYU W, Gong J, Zhu L, Xu T, et al
    MR radiomics unveils neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2024;159:107049.
    PubMed     Abstract available


  85. PRITHVIRAJ
    Comment on "Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer".
    Oral Oncol. 2024;159:107054.
    PubMed    


  86. DINESHKUMAR R
    Letter to the editor: Risk factors associated with ototoxicity in long-term survivors of nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107052.
    PubMed    


  87. VALCENKO A, Zwick A, Schneider L, Linxweiler M, et al
    The tumor cell killing capacity of head and neck cancer patient-derived neutrophils depends on tumor stage, gender and the antibody isotype.
    Oral Oncol. 2024;159:107042.
    PubMed     Abstract available


  88. MIN Y, Liu X, Wei Z, Song G, et al
    Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2024;159:107028.
    PubMed     Abstract available


  89. RENGASAMY G, Priya Veeraraghavan V
    Comment on "The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-) radiotherapy".
    Oral Oncol. 2024;159:107035.
    PubMed    


  90. DHARSHINI RAJATHIRAJAN S
    Commentary on "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.".
    Oral Oncol. 2024;159:107037.
    PubMed    


  91. DHARSHINI RAJATHIRAJAN S
    Commentary on "Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients".
    Oral Oncol. 2024;159:107036.
    PubMed    


  92. VERSCHOOR CP, Santi SA, Singh R, Tharmalingam S, et al
    Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107030.
    PubMed     Abstract available


  93. PAKA LUBAMBA G, Hua Y, Bao M, Zhang G, et al
    Variant of internal jugular vein reconstruction in bilateral radical neck dissection.
    Oral Oncol. 2024;159:107015.
    PubMed     Abstract available


  94. WANG A, Xia H, Li J, Diao P, et al
    Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;159:107016.
    PubMed     Abstract available


  95. PRITHVIRAJ T
    Commentary on "Tumor Habitat-Based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
    Oral Oncol. 2024;159:107018.
    PubMed    


  96. XIAOYU J, Baihong P, Yaozhen L, Shen C, et al
    Preoperative protective stenting of the carotid artery in severe complex head and neck cancer resection.
    Oral Oncol. 2024;158:107012.
    PubMed     Abstract available


  97. PAYNE K, Suriyanarayanan H, Brooks J, Mehanna H, et al
    Exploring the impact of intra-tumoural heterogeneity on liquid biopsy cell-free DNA methylation and copy number in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;158:107011.
    PubMed     Abstract available


  98. ZHANG X, Zheng W, Huang S, Li H, et al
    Xerostomia prediction in patients with nasopharyngeal carcinoma during radiotherapy using segmental dose distribution in dosiomics and radiomics models.
    Oral Oncol. 2024;158:107000.
    PubMed     Abstract available


  99. CHEN J, Cheng H, Liang Y, Lin J, et al
    The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads.
    Oral Oncol. 2024;156:106938.
    PubMed     Abstract available


    August 2024
  100. LECHIEN JR, Hans S
    Survival, Surgical, and functional outcomes of transoral laser microsurgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
    Oral Oncol. 2024;158:107009.
    PubMed     Abstract available


  101. ZHAO J, Ruan X, Wei S, Zheng X, et al
    The first report of bilateral parapharyngeal lymph node metastasis from papillary thyroid carcinoma: A case report.
    Oral Oncol. 2024;158:107006.
    PubMed    


  102. YIN WJ, Mao W, Yang F, Wang MY, et al
    Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions.
    Oral Oncol. 2024;158:107001.
    PubMed     Abstract available


  103. GE Y, Liu H, Huang W, Zhu H, et al
    Immunoinhibitory effects of hypoxia-driven reprogramming of EGR1(hi) and EGR3 positive B cells in the nasopharyngeal carcinoma microenvironment.
    Oral Oncol. 2024;158:106999.
    PubMed     Abstract available


  104. T P
    Commentary on "Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/mHNSCC)".
    Oral Oncol. 2024;158:107010.
    PubMed    


  105. ZHOU X, Shao T, Jia H, Hou L, et al
    Current state, challenges, and future perspective of adaptive radiotherapy: A narrative review of nasopharyngeal carcinoma.
    Oral Oncol. 2024;158:107008.
    PubMed     Abstract available


  106. PRASAD M
    DNA Methylation Mediated Epigenetic Silencing of PD-1 and PD-L1: Therapeutic Implications in Oral Cancer.
    Oral Oncol. 2024 Aug 23:106995. doi: 10.1016/j.oraloncology.2024.106995.
    PubMed    


  107. KNAP RABJERG H, Grau Eriksen J, Soby S
    Impact of antibiotics on PD-1 inhibition in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2024;158:107003.
    PubMed    


  108. DU F, Shao K, Yang Y, Bai X, et al
    Comparative dosimetric analysis of normal brain tissue in patients with Nasopharyngeal carcinoma at different stages after radiation therapy.
    Oral Oncol. 2024;158:106998.
    PubMed     Abstract available


  109. ALSHEIKH S, Su J, O'Sullivan B, Ringash J, et al
    The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy.
    Oral Oncol. 2024;158:107007.
    PubMed     Abstract available


  110. SUN L, Cohen RB, Dimitrios Colevas A
    Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
    Oral Oncol. 2024;158:106997.
    PubMed     Abstract available


  111. HANNA GJ, Jabalee J, Lukens JN, Sun L, et al
    Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
    Oral Oncol. 2024;158:107002.
    PubMed     Abstract available


  112. YUAN J, Wu M, Qiu L, Xu W, et al
    Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2024;158:106980.
    PubMed     Abstract available


  113. YANG R, Li R, Niu X, Zhao Y, et al
    Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study.
    Oral Oncol. 2024;158:106981.
    PubMed     Abstract available


  114. HUSSEIN NI, Molina AH, Sunga GM, Amit M, et al
    Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2024;158:106986.
    PubMed     Abstract available


  115. PAN GS, Sun XM, Kong FF, Wang JZ, et al
    Delta magnetic resonance imaging radiomics features?based nomogram predicts long?term efficacy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2024;157:106987.
    PubMed     Abstract available


  116. QIN G, Liao X, Zhang B, Su Y, et al
    An individualized immune prognostic signature in nasopharyngeal carcinoma.
    Oral Oncol. 2024;157:106985.
    PubMed     Abstract available


  117. TAMIOLAKIS P, Shah A, Dawson R, Ramasamy S, et al
    HPV- associated sinonasal squamous cell carcinoma with FGFR3::TACC3 fusion. A rare case report.
    Oral Oncol. 2024;157:106983.
    PubMed     Abstract available


  118. SHIMIZU H, Kodaira T, Kiyota N, Hayashi R, et al
    Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008.
    Oral Oncol. 2024;157:106976.
    PubMed     Abstract available


  119. SANKAR S
    Letter to editor regarding "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression".
    Oral Oncol. 2024;157:106977.
    PubMed    


  120. SCHAEFFERS AWMA, Scholten HA, van Beers MA, Meussen BW, et al
    The effect of skeletal muscle mass on dose-limiting toxicities during (chemo)radiotherapy in patients with head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2024;157:106978.
    PubMed     Abstract available


    July 2024
  121. MCDOWELL L, Gough K, White I, Corry J, et al
    Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer - A narrative review.
    Oral Oncol. 2024;157:106975.
    PubMed     Abstract available


  122. DAS S, Ghosh Laskar S, V Kane S, D'Cruz AK, et al
    Adjuvant therapy for intermediate risk factors in oral cancer: Can we reach a consensus?
    Oral Oncol. 2024;157:106972.
    PubMed     Abstract available


  123. JEYARAJ G
    Letter to the editor, "Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the head and neck Cancer Registry of Japan.".
    Oral Oncol. 2024;157:106974.
    PubMed    


  124. JEYARAJ G
    Letter to the editor, "Mutation detection in saliva from oral cancer patients".
    Oral Oncol. 2024;157:106929.
    PubMed    


  125. GANESH PS, Pathoor NN, Gopal RK
    Letter to the editor regarding "Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Oral Oncol. 2024;157:106954.
    PubMed     Abstract available


  126. LORINI L, Zigliani G, Morbini P, Salviato E, et al
    Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study).
    Oral Oncol. 2024;157:106950.
    PubMed     Abstract available


  127. JEYACHANDRAN S
    Comment on, "Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes".
    Oral Oncol. 2024;157:106973.
    PubMed     Abstract available


  128. SURESH S
    Comment on: An algorithm for standardization of tumor infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;157:106959.
    PubMed    


  129. WEN YF, Huang WJ, Chen XL, Cai HT, et al
    Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients.
    Oral Oncol. 2024;157:106963.
    PubMed     Abstract available


  130. ICHISAKA T, Sano D, Kijima N, Kawakita D, et al
    Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the Head and Neck Cancer Registry of Japan.
    Oral Oncol. 2024;157:106942.
    PubMed     Abstract available


  131. TINO R, Roach MA, Fuentes GD, Agrawal A, et al
    Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
    Oral Oncol. 2024;157:106944.
    PubMed     Abstract available


  132. LIM CY, Ng GWY, Goh CK, Lee MKC, et al
    Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.
    Oral Oncol. 2024;157:106941.
    PubMed     Abstract available


  133. SHANMUGAM G
    Letter to the editor, "The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.".
    Oral Oncol. 2024;157:106951.
    PubMed    


  134. MEIVELU MOOVENDHAN
    "Letter to the Editor: Next-Generation sequencing (NGS) profiling of matched tumor and Circulating Tumor DNA (ctDNA) in Head and Neck Squamous Cell Carcinoma (HNSCC)".
    Oral Oncol. 2024;157:106940.
    PubMed    


  135. ZENGA J, Himburg HA, Wong SJ, Kearl T, et al
    In silico identification of public neo-antigens in head and neck Cancer for T cell receptor Engineering: Targeting PI3KCA and TP53 missense mutations.
    Oral Oncol. 2024 Jul 14:106947. doi: 10.1016/j.oraloncology.2024.106947.
    PubMed    


  136. DHARMALINGAM JOTHINATHAN MK
    Letter to the Editor, "Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma".
    Oral Oncol. 2024;156:106948.
    PubMed    


  137. SHANMUGAM G
    Commentary on, "Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.".
    Oral Oncol. 2024;156:106952.
    PubMed    


  138. PIYARATHNE NS, Liyanage SN, Rasnayaka RMSGK, Hettiarachchi PVKS, et al
    A comprehensive dataset of annotated oral cavity images for diagnosis of oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2024;156:106946.
    PubMed     Abstract available


  139. MAHDI AGM
    Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer.
    Oral Oncol. 2024;156:106939.
    PubMed     Abstract available


  140. SHANMUGAM G
    Letter to the editor, "Letter to the editor, "Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.".
    Oral Oncol. 2024;156:106935.
    PubMed    


  141. ARUMUGANAINAR D, Sekaran S
    Correspondence on "Global burdens of nasopharyngeal carcinoma in children and young adults: Trends and predictions to 2040".
    Oral Oncol. 2024;156:106933.
    PubMed    


  142. GU LW, Zhang X, Zhang J, Xiao BB, et al
    The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2024;156:106928.
    PubMed     Abstract available


  143. SURESH S
    Commentary on 'Mutation detection in saliva from oral cancer patients'.
    Oral Oncol. 2024;156:106937.
    PubMed    


  144. KASIRAJAN H, Rengasamy G, Priya Veeraraghavan V
    Comment on the "Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module".
    Oral Oncol. 2024;156:106934.
    PubMed    


  145. KANNAN R
    Comments on: Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
    Oral Oncol. 2024;156:106936.
    PubMed    


  146. DAUNGSUPAWONG H, Wiwanitkit V
    Letter to the Editor on "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance".
    Oral Oncol. 2024;156:106930.
    PubMed    


  147. LIOKATIS P, Liokati I, Obermeier K, Smolka W, et al
    Prognostic role of lymph node micrometastasis in oral and oropharyngeal cancer: A systematic review.
    Oral Oncol. 2024;154:106808.
    PubMed     Abstract available


  148. CHEN AM
    Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future.
    Oral Oncol. 2024;154:106850.
    PubMed     Abstract available


  149. SATHISHKUMAR K
    Letter to the editor "risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial ".
    Oral Oncol. 2024;156:106931.
    PubMed    


  150. HARIDEVAMUTHU B
    Letter to the Editor: "Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma".
    Oral Oncol. 2024;156:106913.
    PubMed    


    June 2024
  151. BENJAMIN WJ, Feng AL, Heft Neal M, Bellile E, et al
    Utility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer.
    Oral Oncol. 2024;156:106917.
    PubMed     Abstract available


  152. ZHAO X, Zhou Y, Peng G, Wen L, et al
    Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2024;156:106918.
    PubMed     Abstract available


  153. SARAVANAN M, Singh Carmelin D, Mohanprasanth A, Arockiaraj J, et al
    Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
    Oral Oncol. 2024;156:106911.
    PubMed    


  154. POONGAVANAM SS, Behera A, Dharmalingam Jothinathan MK
    Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
    Oral Oncol. 2024;156:106912.
    PubMed    


  155. JEYARAJ G
    Letter to the editor, "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer".
    Oral Oncol. 2024;156:106906.
    PubMed    


  156. DONG S, Bei W, Lin L, Jiang Y, et al
    Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.
    Oral Oncol. 2024;156:106908.
    PubMed     Abstract available


  157. JEYARAJ G
    Transformative impact of 3D-Printed implants and Virtual surgical planning in oral cancer reconstruction.
    Oral Oncol. 2024;156:106896.
    PubMed    


  158. SHANMUGAM G
    Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.".
    Oral Oncol. 2024;156:106915.
    PubMed    


  159. BASTIEN AJ, Ng J, Cong I, Garcia J, et al
    Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;156:106894.
    PubMed     Abstract available


  160. HARIDEVAMUTHU B
    Letter to the Editor: "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral Cancer".
    Oral Oncol. 2024;155:106902.
    PubMed    


  161. MEIVELU MOOVENDHAN
    Letter to the editor, "Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma".
    Oral Oncol. 2024;155:106903.
    PubMed    


  162. PRASAD M, Sekar R, Murugan R
    Letter to editor on "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
    Oral Oncol. 2024;155:106899.
    PubMed    


  163. SELVI POONGAVANAM S, Behera A, Kumar Dharmalingam Jothinathan M
    Letter to the Editor, "The predictive role of PD-L1 in head and neck Cancer: A systematic review and Meta-Analysis".
    Oral Oncol. 2024;155:106904.
    PubMed    


  164. TOPKAN E, Somay E, Bascil S, Selek U, et al
    Comment on prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
    Oral Oncol. 2024;155:106898.
    PubMed    


  165. HARIDEVAMUTHU B
    Genomic instability in HPV-positive oropharyngeal squamous cell carcinoma: The role of integration sites in treatment response.
    Oral Oncol. 2024;155:106895.
    PubMed    


  166. LEI S, Chen L, Ji P, Li K, et al
    Global burdens of nasopharyngeal carcinoma in children and young adults and predictions to 2040.
    Oral Oncol. 2024;155:106891.
    PubMed     Abstract available


  167. DA MOTA SANTANA LA, Simoes JMD, Santos GA, Gopalsamy RG, et al
    Comment on "Association between COVID 19 exposure and expression of malignant pathological features in oral cancer: A retrospective cohort study".
    Oral Oncol. 2024;155:106877.
    PubMed    


  168. ROOF SA, Jabalee J, Rettig EM, Chennareddy S, et al
    Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
    Oral Oncol. 2024;155:106874.
    PubMed     Abstract available


  169. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    Corrigendum to "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group" [Oral Oncol. 152C (2024) 106744].
    Oral Oncol. 2024 Jun 8:106887. doi: 10.1016/j.oraloncology.2024.106887.
    PubMed    


  170. PRASAD M, Murugan R
    Comment on "The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis".
    Oral Oncol. 2024;155:106890.
    PubMed    


  171. TASOULAS J, Adams GJ, Schrank TP, Agala CB, et al
    Time to treatment for head and neck cancer patients decreased during the early phase of the Covid-19 pandemic.
    Oral Oncol. 2024;155:106879.
    PubMed    


  172. DHARMALINGAM JOTHINATHAN MK
    Letter to the Editor, "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? A multi-institutional study on 366 patients from the ARYFIX collaborative group".
    Oral Oncol. 2024;155:106878.
    PubMed    


  173. BABU S, Krishnan M
    Human papillomavirus and oropharyngeal cancer in HNSCC: A growing concern.
    Oral Oncol. 2024;153:106824.
    PubMed    


  174. PACE GM, Costantino A, Festa BM, Spriano G, et al
    Oropharyngeal squamous cell carcinoma: Treatment (de-) intensification?
    Oral Oncol. 2024;153:106299.
    PubMed    


  175. LU HA, Wang YM, Chih Chen W, Wu CN, et al
    Post-irradiation dysbiosis in patients with nasopharyngeal carcinoma having received radiotherapy - A pilot study.
    Oral Oncol. 2024;154:106864.
    PubMed     Abstract available


  176. KRC R, Mendes W, Molitoris J, Ferris M, et al
    Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.
    Oral Oncol. 2024;154:106875.
    PubMed     Abstract available


    May 2024
  177. XU W, Qiu L, Li F, Fei Y, et al
    Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Oral Oncol. 2024;154:106865.
    PubMed     Abstract available


  178. IMAMURA Y, Kiyota N, Tahara M, Kodaira T, et al
    Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.
    Oral Oncol. 2024;154:106868.
    PubMed     Abstract available


  179. PARK R, Li J, Slebos RJC, Chaudhary R, et al
    Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2024;154:106866.
    PubMed     Abstract available


  180. SARAVANAN M, Carmelin DS, Mohanprasanth A, Arockiaraj J, et al
    Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
    Oral Oncol. 2024;154:106858.
    PubMed    


  181. HESHAM A, David Kim D, Alshamrani Y, AlOtaibi F, et al
    The efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy in recurrent head and neck squamous cell carcinoma. Report of a case and review of the literature.
    Oral Oncol. 2024;154:106863.
    PubMed    


  182. ABBACI M, Villard A, Auperin A, Asmandar S, et al
    Ultra-fast confocal fluorescence microscopy for neck lymph node imaging in head and neck cancer.
    Oral Oncol. 2024;154:106862.
    PubMed     Abstract available


  183. YAO Y, Ouyang Q, Wang S, Li K, et al
    Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
    Oral Oncol. 2024;154:106867.
    PubMed     Abstract available


  184. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    In response to the reply on 'Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes'.
    Oral Oncol. 2024;154:106856.
    PubMed    


  185. COSTANTINO A, Haughey B, Zhu J, Mekhail T, et al
    Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
    Oral Oncol. 2024;154:106855.
    PubMed     Abstract available


  186. PEZZULLA D, Re A, Ferro M, Cilla S, et al
    Lower cranial nerve palsy after hypofractionated radiotherapy in a laryngeal cancer patient: A letter to the editor.
    Oral Oncol. 2024;154:106837.
    PubMed    


  187. ALVES DA MOTA SANTANA L, Gois Floresta L, Maciel Alves EV, Ribeiro Couto G, et al
    Reply to: Comment on "Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes".
    Oral Oncol. 2024;154:106840.
    PubMed    


  188. HE S, Yu H, He L, Liu M, et al
    Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors.
    Oral Oncol. 2024;154:106827.
    PubMed     Abstract available


  189. VAZQUEZ FL, Coracin FL, Arantes KLBF, Ferigatto JL, et al
    An oral cancer screening program in Brazil: Analysis of seven years of outcome after its implementation in the suburban cities of Sao Paulo.
    Oral Oncol. 2024;154:106826.
    PubMed     Abstract available


  190. DE FELICE F, Guerrero Urbano T
    Lower-neck sparing in patients with uninvolved neck nasopharyngeal carcinoma: Unquestioned benefit?
    Oral Oncol. 2024;154:106836.
    PubMed    


  191. HAN N, Zhou D, Ruan M, Yan M, et al
    Corrigendum to "Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer" [Oral Oncol. 145 (2023) 106524].
    Oral Oncol. 2024 May 9:106831. doi: 10.1016/j.oraloncology.2024.106831.
    PubMed    


  192. INVERNIZZI C, Da Silva Ribeiro Mota A, Barbe C, Bouazzi L, et al
    Prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
    Oral Oncol. 2024;153:106833.
    PubMed     Abstract available


  193. PADERNO A, Petrelli F, Lorini L, Capriotti V, et al
    The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2024;153:106799.
    PubMed     Abstract available


  194. LIU Y, Zuo ZC, Zeng XY, Ma J, et al
    Establishing subdivisions of M1 stage nasopharyngeal carcinoma based on decision tree classification: A multicenter retrospective study.
    Oral Oncol. 2024;153:106834.
    PubMed     Abstract available


  195. XU Y, Xu T, Yao Q, Chen J, et al
    Individualized radiology screening for newly diagnosed nasopharyngeal carcinoma.
    Oral Oncol. 2024;153:106828.
    PubMed     Abstract available


  196. ALMANGUSH A, Makitie AA, Leivo I
    Assessment of tumor-infiltrating lymphocytes in head and neck cancer: Clinical scenarios.
    Oral Oncol. 2024;153:106829.
    PubMed    


  197. DAS R, Misra SR
    Author's reply to comment on "awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;153:106832.
    PubMed    


  198. DHARMALINGAM JOTHINATHAN MK
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106811.
    PubMed    


  199. POOJARI M, Madabhavi I, Desai S
    Extraskeletal Ewing's sarcoma of supraglottis: A rare case report.
    Oral Oncol. 2024;152:106789.
    PubMed     Abstract available


  200. MELDGAARD JUSTESEN M, Kronberg Jakobsen K, Fenger Carlander AL, Hjordt Holm Larsen M, et al
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106783.
    PubMed     Abstract available


    April 2024
  201. TONSBEEK AM, Hundepool CA, Roubos J, Rijken B, et al
    Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module.
    Oral Oncol. 2024;153:106813.
    PubMed     Abstract available


  202. MICHIKAWA C, Gleber-Netto FO, Pickering CR, Rao X, et al
    Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer.
    Oral Oncol. 2024;153:106729.
    PubMed     Abstract available


  203. FANG Q, Yuan J, Zhang X, Dai L, et al
    Oncologic and functional results between sentinel lymph node biopsy and elective neck dissection in cT1/2N0 maxillary squamous cell carcinoma.
    Oral Oncol. 2024;152:106810.
    PubMed     Abstract available


  204. YEO BSY, Lee RS, Lim NE, Tan E, et al
    Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
    Oral Oncol. 2024;152:106786.
    PubMed     Abstract available


  205. LI Y, Zhou Y, Zhao C, Liu L, et al
    The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis.
    Oral Oncol. 2024;152:106798.
    PubMed     Abstract available


  206. RAMASAMY P, Sekaran S, Ganapathy D
    Oral cancer burden in tribal populations residing in India.
    Oral Oncol. 2024;152:106801.
    PubMed    


  207. SEKAR D
    Comment on betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106800.
    PubMed    


  208. SARAVANAN M
    Comment on "Nanomedicine, an emerging therapeutic strategy for oral cancer therapy".
    Oral Oncol. 2024;152:106806.
    PubMed    


  209. RICARDO ELIAS DE MELO P, Agra Monteiro M, Henrique Rocha Aragao H, Vitoria de Araujo Lopes N, et al
    Comment on "Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;152:106802.
    PubMed    


  210. SMITH JD, Heft-Neal ME, Rosko AJ, Chepeha DB, et al
    Upfront neck dissection to guide single-modality therapy for early stage supraglottic squamous cell carcinoma.
    Oral Oncol. 2024;152:106803.
    PubMed    


  211. KONO M, Saito S, Rokugo M, Egloff AM, et al
    Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Oral Oncol. 2024;152:106795.
    PubMed     Abstract available


  212. SEGNA E, Civita F, Denaro N, Beltramini GA, et al
    Cavernous sinus metastasis in head and neck cancer: Focus on oral squamous cell cancer.
    Oral Oncol. 2024;152:106784.
    PubMed     Abstract available


  213. SIVAPERUMAL P, Ganapathy D, Kamala K
    Revolutionizing oral cancer treatment: Harnessing the potential of adaptive CARneg T cell therapy.
    Oral Oncol. 2024;152:106794.
    PubMed    


  214. RAJAKUMAR HK, Coimbatore Sathyabal V, Vivekanandam A, Nasrin Jabarulla K, et al
    Evaluation of nuclear morphometry in exfoliative cytology of buccal mucosa in patients with high risk of oral cancer.
    Oral Oncol. 2024;152:106793.
    PubMed     Abstract available


  215. SARAVANAN M
    Comment on "The microbiome and oral cancer: More questions than answers".
    Oral Oncol. 2024;152:106792.
    PubMed    


  216. ARAGAO HHR, Monteiro MA, Lopes NVA, Cunha JLS, et al
    Comment on "Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study".
    Oral Oncol. 2024;152:106788.
    PubMed    


  217. DAS R, Misra SR, Nayak A
    Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?
    Oral Oncol. 2024;152:106790.
    PubMed    


  218. XIAO X, Shi Z, Song Z
    Comment on circulatory mitochondrial DNA as a novel biomarker for head and neck cancers.
    Oral Oncol. 2024;152:106785.
    PubMed    


  219. GASNE C, Atallah S, Dauzier E, Thariat J, et al
    Twelve years after: The french national network on rare head and neck tumours (REFCOR).
    Oral Oncol. 2024;151:106762.
    PubMed     Abstract available


  220. MALI SB
    Role of telemedicine in head neck cancer.
    Oral Oncol. 2024;151:106746.
    PubMed     Abstract available


  221. MIRIMOGHADDAM M, Bohlouli B, Lai H, Viegas S, et al
    Trends and predictors of unplanned hospitalization among oral and oropharyngeal cancer patients; an 8-year population-based study.
    Oral Oncol. 2024;151:106742.
    PubMed     Abstract available


    March 2024
  222. MEGAHED R, Prabhu AV, Mack DP, Gholami S, et al
    Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series.
    Oral Oncol. 2024;152:106778.
    PubMed     Abstract available


  223. LORINI L, Gili R, Salvestrini V, Morelli I, et al
    De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
    Oral Oncol. 2024;152:106768.
    PubMed     Abstract available


  224. XIROU V, Moutafi M, Bai Y, Nwe Aung T, et al
    An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;152:106750.
    PubMed     Abstract available


  225. HONG RL, Yen CJ, Lien MY, Cheng R, et al
    Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106760.
    PubMed     Abstract available


  226. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group.
    Oral Oncol. 2024;152:106744.
    PubMed     Abstract available


  227. TOYA R, Fukugawa Y, Saito T, Matsuyama T, et al
    Radiation Therapy Oncology Group 8502 "QUAD shot" regimen using volumetric modulated arc therapy for incurable head and neck cancer.
    Oral Oncol. 2024;151:106752.
    PubMed     Abstract available


  228. RUIZ-TORRES DA, Naegele S, Podury A, Wirth L, et al
    Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis.
    Oral Oncol. 2024;151:106761.
    PubMed     Abstract available


  229. SIMON L, Paly J, Park E, Samuels-Kalow M, et al
    Medicare dental coverage for patients with head and neck cancer: An opportunity in need of advocates.
    Oral Oncol. 2024 Mar 15:106754. doi: 10.1016/j.oraloncology.2024.106754.
    PubMed    


  230. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    Comment on "advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with Teledentistry for Better Patient Outcomes".
    Oral Oncol. 2024;151:106758.
    PubMed    


  231. RAJANATHADURAI J, Sindya J, Madar IH, Perumal E, et al
    Exosomal immune checkpoint protein (PD-L1): Hidden player in PD-1/PD-L1 blockade immunotherapy resistance in oral cancer.
    Oral Oncol. 2024;151:106748.
    PubMed    


  232. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
    Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
    Oral Oncol. 2024;151:106749.
    PubMed     Abstract available


  233. FERRARO T, Pershad AR, Arora S, Lee E, et al
    The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
    Oral Oncol. 2024;151:106743.
    PubMed     Abstract available


  234. KIM DH, Lim ST, Kim HR, Kang EJ, et al
    Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
    Oral Oncol. 2024;151:106739.
    PubMed     Abstract available


  235. SANTANA LADM, Floresta LG, Alves EVM, Melo LMR, et al
    Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes.
    Oral Oncol. 2024;151:106741.
    PubMed    


  236. CHEN K, Shi M, Mo S, Liu T, et al
    Clinical features and prognostic factors of nasopharyngeal carcinoma with brain metastases.
    Oral Oncol. 2024;151:106738.
    PubMed     Abstract available


  237. DING C, Dai DY, Luo ZK, Wang GY, et al
    Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
    Oral Oncol. 2024;151:106725.
    PubMed     Abstract available


  238. LU X, Zhang JL, Zhai X, Liu Q, et al
    A case report on a nasal and oral cavity involving large solitary fibrous tumor and comprehensive review of case literature.
    Oral Oncol. 2024;150:106715.
    PubMed     Abstract available


  239. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
    Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
    Oral Oncol. 2024;150:106687.
    PubMed     Abstract available


    February 2024
  240. VAN SCHAIK JE, van der Vegt B, Slagter-Menkema L, van der Laan BFAM, et al
    Identification of new head and neck squamous cell carcinoma molecular imaging targets.
    Oral Oncol. 2024;151:106736.
    PubMed     Abstract available


  241. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
    Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
    Oral Oncol. 2024;151:106703.
    PubMed     Abstract available


  242. AHMED AA, Sborchia M, Bye H, Roman-Escorza M, et al
    Mutation detection in saliva from oral cancer patients.
    Oral Oncol. 2024;151:106717.
    PubMed     Abstract available


  243. CHEN QY, Guo SS, Luo Y, Qu S, et al
    Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
    Oral Oncol. 2024;151:106723.
    PubMed     Abstract available


  244. FANCELLO G, Jiang S, Licci G, Gallo O, et al
    Comments on the article titled "Factors associated with unknown primary status in head and neck squamous cell carcinoma": Is the N status the overlooked elephant in the room?
    Oral Oncol. 2024;151:106727.
    PubMed    


  245. HU J, Huang Q, Hu W, Liang F, et al
    Tumor volume instead of recurrent T category predicts clinical outcome of patients with locally recurrent nasopharyngeal carcinoma salvaged by carbon ion radiation therapy.
    Oral Oncol. 2024;151:106683.
    PubMed     Abstract available


  246. CABEZAS-CAMARERO S, Vazquez Masedo G, Puebla-Diaz F, Corona JA, et al
    Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer.
    Oral Oncol. 2024;150:106719.
    PubMed     Abstract available


  247. SANTANA NCM, de Sena ACVP, Rocha PADS, de Arruda JAA, et al
    Oral cancer and oral potentially malignant disorders in patients with Fanconi anemia - A systematic review.
    Oral Oncol. 2024;150:106699.
    PubMed     Abstract available


  248. BATTISTI A, Della Monaca M, Di Giorgio D, Priore P, et al
    Extranodal follicular dendritic cell sarcoma of the tonsil: An extremely rare clinical entity.
    Oral Oncol. 2024;149:106690.
    PubMed     Abstract available


  249. ADEN AA, Olawuni FO, Abdel-Halim CN, Zhu AQ, et al
    Association Between Social Determinants of Health, Distance from Treatment Center, and Treatment Type with Outcomes in Human Papillomavirus Associated Oropharyngeal cancer.
    Oral Oncol. 2024;149:106675.
    PubMed     Abstract available


  250. HEIRMAN AN, Dirven R, van der Molen L, Schreuder WH, et al
    The development of a decision aid for patients with operable oropharyngeal carcinoma in the Netherlands - A mixed methods study.
    Oral Oncol. 2024;149:106677.
    PubMed     Abstract available


  251. MEIRELLES DP, Da Costa AAS, Sousa-Neto SS, Cardoso SV, et al
    Methodological challenges in identifying histological prognostic markers for squamous cell carcinoma of the lip, mouth, and oropharynx.
    Oral Oncol. 2024;149:106665.
    PubMed    


  252. BALASAMY S, Sundramoorthy AK
    EGFR-targeted fluorescence imaging for precision margin assessment in oral cancer surgery.
    Oral Oncol. 2024;150:106712.
    PubMed    


    January 2024
  253. OCHOA SCUSSIATTO H, Stenson KM, Al-Khudari S, Jelinek MJ, et al
    Air pollution is associated with increased incidence-rate of head and neck cancers: A nationally representative ecological study.
    Oral Oncol. 2024;150:106691.
    PubMed     Abstract available


  254. LI L, Chen L, Fan M, Tian Y, et al
    A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma.
    Oral Oncol. 2024;150:106695.
    PubMed     Abstract available


  255. STOGBAUER F, Otto R, Johrens K, Tinhofer I, et al
    Molecular subtyping of head and neck cancer - Clinical applicability and correlations with morphological characteristics.
    Oral Oncol. 2024;149:106678.
    PubMed     Abstract available


  256. JAGADEESHAN S, Suryamohan K, Shin N, Mathukkada S, et al
    Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
    Oral Oncol. 2024;149:106688.
    PubMed     Abstract available


  257. PUJOL A, Leon X, Holgado A, Valero C, et al
    External validation of the GETTEC algorithm for elective neck dissection in patients candidates for salvage total laryngectomy.
    Oral Oncol. 2024;149:106686.
    PubMed     Abstract available


  258. SHENKER RF, Razavian NB, D'Agostino RB Jr, Mowery YM, et al
    Clinical outcomes of oropharyngeal squamous cell carcinoma stratified by human papillomavirus subtype: A systematic review and meta-analysis.
    Oral Oncol. 2024;148:106644.
    PubMed     Abstract available


  259. COSTANTINO A, Sampieri C, Pace GM, Festa BM, et al
    Development of machine learning models for the prediction of long-term feeding tube dependence after oral and oropharyngeal cancer surgery.
    Oral Oncol. 2024;148:106643.
    PubMed     Abstract available


    December 2023
  260. TOPKAN E, Somay E, Selek U
    Comment on "A systematic review and meta-analysis of osteoradionecrosis following proton therapy in patients with head and neck cancer".
    Oral Oncol. 2023;149:106679.
    PubMed    


  261. AKHTAR A, Akhtar R, Nasir BM
    Response to "Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma".
    Oral Oncol. 2023;149:106674.
    PubMed    


  262. SICHERO L, Goncalves MG, Bettoni F, Coser EM, et al
    Detection of serum biomarkers of HPV-16 driven oropharynx and oral cavity cancer in Brazil.
    Oral Oncol. 2023;149:106676.
    PubMed     Abstract available


  263. BILA M, Franken A, Van Dessel J, Garip M, et al
    Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2023;149:106664.
    PubMed     Abstract available


  264. GUO Y, Nakashima T, Cho BC, Lim DW, et al
    Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific.
    Oral Oncol. 2023;148:106657.
    PubMed     Abstract available


  265. HUANG H, Chen Z, Zhu M, Deng X, et al
    Discontinuation and nonpublication of nasopharyngeal carcinoma clinical trials.
    Oral Oncol. 2023;148:106656.
    PubMed     Abstract available


  266. CHEN W, Yu X, Li H, Yuan S, et al
    Single-cell RNA-seq reveals MIF-(CD74 + CXCR4) dependent inhibition of macrophages in metastatic papillary thyroid carcinoma.
    Oral Oncol. 2023;148:106654.
    PubMed     Abstract available


  267. NEO J, Yip PL, Ong EHW, Miao J, et al
    Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma.
    Oral Oncol. 2023;148:106655.
    PubMed     Abstract available


  268. WILLIAMSON A, Moen CM, Slim MAM, Warner L, et al
    Transoral robotic surgery without adjuvant therapy: A systematic review and meta-analysis of the association between surgical margins and local recurrence.
    Oral Oncol. 2023;147:106610.
    PubMed     Abstract available


  269. SILVA CUNHA JL
    Comment on "Decisional regret, symptom burden, and quality of life following transoral robotic surgery for oropharyngeal cancer".
    Oral Oncol. 2023;147:106626.
    PubMed    


  270. TIRELLI G, Boscolo-Rizzo P
    Palatoglossus muscle involvement in oropharynx Carcinoma: A pitfall in the T4 category definition of the 8th edition of the TNM staging system?
    Oral Oncol. 2023;147:106627.
    PubMed    


  271. BARROS EF, Cunha JLS, de Sousa DP, Pereira RVS, et al
    A destructive sinonasal organizing hematoma mimicking malignancy.
    Oral Oncol. 2023;147:106619.
    PubMed     Abstract available


    November 2023
  272. KALAVACHERLA S, Li V, Voora R, Victor M, et al
    Factors associated with unknown primary status in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;148:106650.
    PubMed     Abstract available


  273. ZHANG S, Zheng M, Tian H, Liu W, et al
    Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
    Oral Oncol. 2023;148:106632.
    PubMed     Abstract available


  274. CHIU KW, Yu TP, Kao YS
    A systematic review and meta-analysis of osteoradionecrosis following proton therapy in patients with head and neck cancer.
    Oral Oncol. 2023;148:106649.
    PubMed     Abstract available


  275. DE SENA ACVP, de Arruda JAA, Felix FA, Tavares TS, et al
    Oral carcinoma in situ in a middle-aged woman with systemic sclerosis: Report of a rare case and literature review.
    Oral Oncol. 2023;148:106646.
    PubMed     Abstract available


  276. HES C, Desilets A, Tonneau M, El Ouarzadi O, et al
    Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2023;148:106623.
    PubMed     Abstract available


  277. GAFFNEY J, Ramzan A, Dinizulu T, Maley C, et al
    Association of follow-up imaging frequency with temporal incidence and patterns of distant failure following (chemo) radiotherapy for HPV related oropharyngeal cancer.
    Oral Oncol. 2023;148:106645.
    PubMed     Abstract available


  278. CHEN AM, Harris JP, Tjoa T, Haidar Y, et al
    Racial disparities in the timely receipt of adjuvant radiotherapy for head and neck cancer.
    Oral Oncol. 2023;147:106611.
    PubMed     Abstract available


  279. TAKESHITA N, Enokida T, Okano S, Fujisawa T, et al
    Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Oral Oncol. 2023;147:106615.
    PubMed     Abstract available


  280. YU SM, Hsu CC, Hsueh SW, Hung CY, et al
    Frailty assessment by two screening instruments in non-elderly patients with head and neck cancer.
    Oral Oncol. 2023;147:106621.
    PubMed     Abstract available


  281. HARRINGTON KJ, Cohen EEW, Soulieres D, Dinis J, et al
    Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
    Oral Oncol. 2023;147:106587.
    PubMed     Abstract available


  282. ABDEL-HALIM CN, O'Byrne TJ, Graves JP, Akpala CO, et al
    Patterns and distribution of regional nodal involvement and recurrence in a surgically treated oropharyngeal squamous cell carcinoma cohort at a tertiary center.
    Oral Oncol. 2023;146:106569.
    PubMed     Abstract available


  283. BARTEMES KR, Gochanour BR, Routman DM, Ma DJ, et al
    Assessing the capacity of methylated DNA markers of cervical squamous cell carcinoma to discriminate oropharyngeal squamous cell carcinoma in human papillomavirus mediated disease.
    Oral Oncol. 2023;146:106568.
    PubMed     Abstract available


  284. WARD MC, Wallander ML, Kuremsky JG, Dhakal R, et al
    Radiation therapy for cT1-2 carcinoma of the palatine tonsil diagnosed via a simple tonsillectomy: Dosimetry and patterns of care in the IMRT era.
    Oral Oncol. 2023;146:106557.
    PubMed     Abstract available


  285. KWON JJY, Liu AQ, Milner TD, Prisman E, et al
    Decisional regret, symptom burden, and quality of life following transoral robotic surgery for oropharyngeal cancer.
    Oral Oncol. 2023;146:106537.
    PubMed     Abstract available


  286. HERMSEN MA, Lechner M, Oliveira Ferrer L, Trama A, et al
    EUSICA/COST IMMUNO-model workshop fostering collaboration to advance sinonasal cancer research: A meeting report.
    Oral Oncol. 2023;146:106543.
    PubMed     Abstract available


  287. SARODE GS, Sarode SC, Sharma N
    Comment on "Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening".
    Oral Oncol. 2023;147:106614.
    PubMed    


    October 2023
  288. ANSARI E, Ganry L, Van Cann EM, de Bree R, et al
    Impact of low skeletal muscle mass on postoperative complications in head and neck cancer patients undergoing free flap reconstructive surgery - A systematic review and meta-analysis.
    Oral Oncol. 2023;147:106598.
    PubMed     Abstract available


  289. LIU ZQ, Zhao YN, Wu YS, Zhang BY, et al
    Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2023;147:106583.
    PubMed     Abstract available


  290. BATOOL S, Sethi RKV, Wang A, Dabekaussen K, et al
    Circulating tumor-tissue modified HPV DNA testing in the clinical evaluation of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV study.
    Oral Oncol. 2023;147:106584.
    PubMed     Abstract available


  291. SARAVANAN M, Sampath S, Arockiaraj J
    The use of advanced transoral robotic surgery in the treatment of oropharynx squamous cell carcinoma: A modern alternative for open surgery.
    Oral Oncol. 2023;145:106522.
    PubMed    


  292. TURNER MT, Chung J, Noorkbash S, Topf MC, et al
    Complications following salvage transoral robotic surgery with and without reconstruction: A systematic review of the literature.
    Oral Oncol. 2023;145:106467.
    PubMed     Abstract available


  293. ROBERTI E, Merlano M, Ravanelli M, Alberti A, et al
    Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;145:106540.
    PubMed     Abstract available


  294. REVERDY T, Varnier R, de Talhouet S, Duplomb S, et al
    Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck.
    Oral Oncol. 2023;145:106533.
    PubMed     Abstract available


  295. KEMNADE JO, Florez M, Sabichi A, Zhang J, et al
    Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population.
    Oral Oncol. 2023;145:106536.
    PubMed     Abstract available


    September 2023
  296. SHAIKH MH, Dawson A, Prokopec SD, Barrett JW, et al
    Loss of LRP1B expression drives acquired chemo and radio-resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2023;146:106580.
    PubMed     Abstract available


  297. CAVALIERI S, Platini F, Barretta F, Nuzzolese I, et al
    Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
    Oral Oncol. 2023;146:106579.
    PubMed     Abstract available


  298. MALI SB
    Role of in vivo imaging in Head and Neck cancer management.
    Oral Oncol. 2023;146:106575.
    PubMed     Abstract available


  299. CHOI SY, Shim J, Gu DE, Kim SY, et al
    Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening.
    Oral Oncol. 2023;146:106571.
    PubMed     Abstract available


  300. GUO J, He Y, Lin C, Jiang Q, et al
    Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma.
    Oral Oncol. 2023;146:106574.
    PubMed     Abstract available


  301. SINGH R, Song S
    Clinical outcomes following observation, post-operative radiation therapy, or post-operative chemoradiation for HPV-associated oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2023;146:106493.
    PubMed     Abstract available


  302. SHAH R, Tyagi S, Liu C, Judson B, et al
    Extra imaging beyond NCCN surveillance guidelines is cost effective for HPV- but not HPV+ oropharyngeal cancer.
    Oral Oncol. 2023;146:106564.
    PubMed    


  303. MANN JE, Smith JD, Kulkarni A, Foltin SK, et al
    Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;146:106562.
    PubMed     Abstract available


  304. SAHA S, Patil VM, Noronha V, Menon N, et al
    Real world data on long term outcome of neoadjuvant chemotherapy in locally advanced esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation - Results from a single centre study.
    Oral Oncol. 2023;144:106486.
    PubMed     Abstract available


  305. CANAHUATE G, Wentzel A, Mohamed ASR, van Dijk LV, et al
    Spatially-aware clustering improves AJCC-8 risk stratification performance in oropharyngeal carcinomas.
    Oral Oncol. 2023;144:106460.
    PubMed     Abstract available


    August 2023
  306. VIEIRA GS, Perin MY, Figueiredo-Maciel T, Risuenho AJG, et al
    Induction chemotherapy response of HPV-related multiphenotypic sinonasal carcinoma: First-ever reported therapeutic outcome and a brief literature review.
    Oral Oncol. 2023;146:106555.
    PubMed     Abstract available


  307. XU YC, Chen KH, Liang Y, Chen KQ, et al
    Efficacy of induction chemotherapy in lymph node-positive stage III nasopharyngeal carcinoma and identification of beneficiaries based on clinical features: A propensity score matching analysis.
    Oral Oncol. 2023;146:106554.
    PubMed     Abstract available


  308. TASOULAS J, Schrank TP, Smith BD, Agala CB, et al
    Time to treatment patterns of head and neck cancer patients before and during the Covid-19 pandemic.
    Oral Oncol. 2023;146:106535.
    PubMed     Abstract available


  309. CHARTERS E, Loy J, Wu R, Cheng K, et al
    Feasibility study of intensive intervention using novel trismus device during adjuvant radiation for head and neck cancer: Restorabite(TM).
    Oral Oncol. 2023;146:106558.
    PubMed    


  310. AL-MANEI K, Sobkowiak MJ, Nagadia RH, Heymann R, et al
    Mycobiota profile of oral fungal infections in head and neck cancer patients receiving radiotherapy: A 6-year retrospective MALDI-TOF mass spectrometry study.
    Oral Oncol. 2023;146:106556.
    PubMed     Abstract available


  311. ZHANG L, Liao Y
    Comment on: Efficacy of Anti-PD1 blockade in treating recurrent or metastatic nasopharyngeal cancer: A systematic review and meta-analysis.
    Oral Oncol. 2023;143:106435.
    PubMed    


  312. BHAMBHANI C, Sandford E, Haring CT, Brummel C, et al
    Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma.
    Oral Oncol. 2023;143:106436.
    PubMed     Abstract available


    July 2023
  313. DOLL C, Bigus S, Hofmann E, Mrosk F, et al
    Sentinel lymph node biopsy in recurrent or secondary oral squamous cell carcinoma after previous neck dissection.
    Oral Oncol. 2023;145:106494.
    PubMed     Abstract available


  314. GAN M, Harris JP, Truong A, Nabar R, et al
    Timing of chemotherapy and radiation delivery for patients receiving chemoradiation for head and neck cancer: When does "concurrent" mean concurrent?
    Oral Oncol. 2023;145:106492.
    PubMed     Abstract available


  315. MULLER M, Li J, Giger R, Elicin O, et al
    Head and neck cancer with synchronous nodules of the lung as a diagnostic and therapeutic challenge - A systematic review.
    Oral Oncol. 2023;145:106529.
    PubMed     Abstract available


  316. WEI F, Fang R, Lyu K, Liao J, et al
    Exosomal PD-L1 derived from head and neck squamous cell carcinoma promotes immune evasion by activating the positive feedback loop of activated regulatory T cell-M2 macrophage.
    Oral Oncol. 2023;145:106532.
    PubMed     Abstract available


  317. WATSON E, El Maghrabi A, Lee JH, Pu J, et al
    Implication of dental insurance status on patterns of pre-radiation dental extraction and risk of osteoradionecrosis of the jaw in head-and-neck cancer patients.
    Oral Oncol. 2023;145:106527.
    PubMed     Abstract available


  318. NEWMAN S, Cowart JH, Omar N, Martin E, et al
    HPV-associated oropharyngeal Adenosquamous carcinoma with early metastatic disease detected by ctDNA.
    Oral Oncol. 2023;145:106526.
    PubMed     Abstract available


  319. HAN N, Zhou D, Ruan M, Yan M, et al
    Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer.
    Oral Oncol. 2023;145:106524.
    PubMed     Abstract available


  320. NGAMPHAIBOON N, Chairoungdua A, Dajsakdipon T, Jiarpinitnun C, et al
    Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2023;145:106520.
    PubMed     Abstract available


  321. WANG G, Dong Z, Huang C, Du X, et al
    The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2023;145:106500.
    PubMed     Abstract available


  322. VIMALRAJ S, Sekaran S
    Exploring the potential of MiRNAs as predictive biomarkers for radioresistance in nasopharyngeal carcinoma.
    Oral Oncol. 2023;145:106521.
    PubMed    


  323. YOKOTA Y, Hasegawa T, Yamakawa N, Rin S, et al
    Comparison of the 8th edition of TNM staging of oral cancer with the 7th edition and its prognostic significance using clinical depth of invasion and extranodal extension.
    Oral Oncol. 2023;145:106519.
    PubMed     Abstract available


  324. KO K, Takahashi T, Honda K, Horii A, et al
    Avoiding total thyroidectomy for ectopic papillary thyroid carcinoma arising from the lateral neck.
    Oral Oncol. 2023;145:106501.
    PubMed    


  325. LI D, Li C, Shi S
    Letter to the editor: The efficacy and safety of VEGF/VEGFR inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2023;145:106497.
    PubMed    


  326. PENG WS, Xing X, Li YJ, Ding JH, et al
    Prognostic nomograms for nasopharyngeal carcinoma with nodal features and potential indication for N staging system: Validation and comparison of seven N stage schemes.
    Oral Oncol. 2023;144:106438.
    PubMed     Abstract available


  327. ZENGA J, Awan M, Hadi Razeghi Kondelaji M, Hansen C, et al
    Photoactivated HPPH-Liposomal therapy for the treatment of HPV-Negative head and neck cancer.
    Oral Oncol. 2023;144:106487.
    PubMed     Abstract available


  328. CHEPEHA DB, Esemezie AO, Philteos J, Brown DH, et al
    Glossectomy for the treatment of oral cavity carcinoma: Quantitative, functional and patient-reported quality of life outcomes differ by four glossectomy defects.
    Oral Oncol. 2023;142:106431.
    PubMed     Abstract available


  329. EVERTON ASSUNCAO RIBEIRO DA CO, Luz Santos I, Julia Andrade Pereira Soares M, Dos Reis de Paula I, et al
    A case of metastatic NUT carcinoma of the nasal cavity.
    Oral Oncol. 2023;142:106432.
    PubMed    


    June 2023
  330. HE M, Gouda M, Gires O
    EpCAM and EGFR crosstalk in the development of resistance towards Cetuximab treatment in head and neck cancer.
    Oral Oncol. 2023;143:106465.
    PubMed    


  331. YEUNG C, Meyers BM, Kartolo A
    Management of metastatic head and neck Cancer: An all-in, kitchen-sink Approach?
    Oral Oncol. 2023;143:106444.
    PubMed    


  332. KOYUNCU CF, Frederick MJ, Thompson LDR, Corredor G, et al
    Machine learning driven index of tumor multinucleation correlates with survival and suppressed anti-tumor immunity in head and neck squamous cell carcinoma patients.
    Oral Oncol. 2023;143:106459.
    PubMed     Abstract available


  333. PANDIAR D, Nayanar SK, Nair V
    Papillary thyroid carcinoma arising in thyroglossal duct cyst: A case report with long term follow-up.
    Oral Oncol. 2023;143:106439.
    PubMed    


    May 2023
  334. UMEMORI K, Ono K, Eguchi T, Kawai H, et al
    EpEX, the soluble extracellular domain of EpCAM, resists cetuximab treatment of EGFR-high head and neck squamous cell carcinoma.
    Oral Oncol. 2023;142:106433.
    PubMed     Abstract available


  335. HIGGINSON JA, Breik O, Thompson AH, Ashrafian H, et al
    Diagnostic accuracy of intraoperative margin assessment techniques in surgery for head and neck squamous cell carcinoma: A meta-analysis.
    Oral Oncol. 2023;142:106419.
    PubMed     Abstract available


  336. WARNAKULASURIYA S
    "Textbook outcome" as a quality metric of care in predicting survival from oral cancer.
    Oral Oncol. 2023;141:106416.
    PubMed    


  337. DING H, Wu C, Sun W, Zhan Q, et al
    NUDT5-Determines the fate of head and neck squamous cell carcinoma cells under endoplasmic reticulum stress by catalyzing nuclear ATP production to promote DNA repair.
    Oral Oncol. 2023;141:106397.
    PubMed     Abstract available


  338. WANG Y, Gao Y, Yuan L, Zhang J, et al
    Retraction notice to "Psychological needs and associated factors among perioperative patients with oral cancer" [Oral Oncol. 123 (2021) 105615].
    Oral Oncol. 2023 May 5:106394. doi: 10.1016/j.oraloncology.2023.106394.
    PubMed    


  339. RETTIG EM, Waterboer T, Sim E, Faden DL, et al
    Relationship of HPV16 E6 seropositivity with circulating tumor tissue modified HPV16 DNA before head and neck cancer diagnosis.
    Oral Oncol. 2023;141:106417.
    PubMed    


    April 2023
  340. MISRA SR, Mohapatra SSG, Das R
    Comment on "Elective neck dissection: Desideratum or overkill?".
    Oral Oncol. 2023;141:106403.
    PubMed    


  341. HUE J, Valinciute Z, Thavaraj S, Veschini L, et al
    Multifactorial estimation of clinical outcome in HPV-associated oropharyngeal squamous cell carcinoma via automated image analysis of routine diagnostic H&E slides and neural network modelling.
    Oral Oncol. 2023;141:106399.
    PubMed     Abstract available


  342. BOSCOLO-RIZZO P, Tirelli G, Polesel J, Sia E, et al
    TERT promoter mutations in head and neck squamous cell carcinoma: A systematic review and meta-analysis on prevalence and prognostic significance.
    Oral Oncol. 2023;140:106398.
    PubMed     Abstract available


  343. YANG TH, Xirasagar S, Cheng YF, Chen CS, et al
    Trends in the incidence of head and neck cancer: A nationwide population-based study.
    Oral Oncol. 2023;140:106391.
    PubMed     Abstract available


  344. MERCHANT YP, Shah A
    Elective neck dissection: Desideratum or overkill?
    Oral Oncol. 2023;140:106389.
    PubMed    


  345. ARAUJO ALD, Moraes MC, Perez-de-Oliveira ME, Silva VMD, et al
    Machine learning for the prediction of toxicities from head and neck cancer treatment: A systematic review with meta-analysis.
    Oral Oncol. 2023;140:106386.
    PubMed     Abstract available


  346. PATEL ND, Cabrera CI, Fowler NM, Li S, et al
    Incidence and medical complications of COVID-19 in the total laryngectomy population: A population-based study.
    Oral Oncol. 2023;139:106353.
    PubMed     Abstract available


  347. COMER JC, Harris AB, Hess AO, Hitchcock KE, et al
    Does lymphovascular invasion predict survival in oral cancer? A population-based analysis.
    Oral Oncol. 2023;140:106387.
    PubMed     Abstract available


    March 2023
  348. ZUO N, Ma L, Liu T, Hu W, et al
    Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;140:106367.
    PubMed     Abstract available


  349. SAMPIERI C, Costantino A, Pirola F, Kim D, et al
    Neoadjuvant chemotherapy combined with transoral robotic surgery for stage III and IV laryngeal and hypopharyngeal carcinomas.
    Oral Oncol. 2023;140:106371.
    PubMed     Abstract available


  350. HERNANDO-CALVO A, Mirallas O, Marmolejo D, Saavedra O, et al
    Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients.
    Oral Oncol. 2023;140:106364.
    PubMed     Abstract available


  351. CHIEN CY, Wang CP, Lee LY, Lee SR, et al
    Indications for elective neck dissection in cT1N0M0 oral cavity cancer according to the AJCC eight edition: A nationwide study.
    Oral Oncol. 2023;140:106366.
    PubMed     Abstract available


  352. LAMBERT T, Tasoulas J, Flores M, Sheth S, et al
    Circulating tumor HPV DNA as an alternative method to determine HPV status in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;140:106361.
    PubMed     Abstract available


  353. SCHEFF NN, Nilsen ML, Li J, Harris AL, et al
    The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2023;140:106363.
    PubMed     Abstract available


  354. BANOUB RG, Crippen MM, Fiorella MA, Ross HM, et al
    Variance in 3D anatomic localization of surgical margins based on conventional margin labeling in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;139:106360.
    PubMed     Abstract available


  355. ZHANG L, Freeman T, Sun S, Bhateja P, et al
    The use of plasma circulating tumor DNA for early detection of oligometastatic disease in HPV positive oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;139:106357.
    PubMed    


  356. DE FELICE F
    Docetaxel plus radiotherapy for head and neck cancer.
    Oral Oncol. 2023;139:106359.
    PubMed    


  357. ECONOMOPOULOU P, Spathis A, Kotsantis I, Maratou E, et al
    Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
    Oral Oncol. 2023;139:106358.
    PubMed     Abstract available


  358. DE SOUSA LG, Lazar Neto F, Dal Lago EA, Sikora A, et al
    Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma.
    Oral Oncol. 2023;138:106311.
    PubMed     Abstract available


    February 2023
  359. LI SC, Deng SW, Sun XS, Lan KQ, et al
    A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (>/=2 lines) anti-programmed death-1 monotherapy.
    Oral Oncol. 2023;139:106336.
    PubMed     Abstract available


  360. GUERLAIN J, Marhic A, Casiraghi O, Lumbroso J, et al
    Occult nodal metastases in T1-T2cN0 oral squamous cell carcinoma: Correlation between sentinel node positivity and completion neck dissection analysis.
    Oral Oncol. 2023;139:106338.
    PubMed     Abstract available


  361. PARIKH AS, Yu VX, Flashner S, Okolo OB, et al
    Patient-derived three-dimensional culture techniques model tumor heterogeneity in head and neck cancer.
    Oral Oncol. 2023;138:106330.
    PubMed     Abstract available


  362. XIAO Y, Mao L, Yang QC, Wang S, et al
    CD103 blockade impair anti-CTLA-4 immunotherapy in oral cancer.
    Oral Oncol. 2023;138:106331.
    PubMed     Abstract available


  363. RYGALSKI CJ, Huttinger ZM, Zhao S, Brock G, et al
    High surgical volume is associated with improved survival in head and neck cancer.
    Oral Oncol. 2023;138:106333.
    PubMed     Abstract available


  364. BALLAL Y, Gete M, Su J, O'Sullivan B, et al
    The collateral impact of the COVID-19 pandemic on HPV-positive oropharyngeal cancer diagnosis.
    Oral Oncol. 2023;138:106332.
    PubMed     Abstract available


  365. BOOT PA, Mes SW, de Bloeme CM, Martens RM, et al
    Magnetic resonance imaging based radiomics prediction of Human Papillomavirus infection status and overall survival in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;137:106307.
    PubMed     Abstract available


    January 2023
  366. VAN BEERS MA, Schreuder WH, Balm AJM, van Dijk BAC, et al
    Is locally advanced head and neck cancer 'increasing' in the Netherlands? The paradox of absolute numbers, standardized incidence rates and proportional share.
    Oral Oncol. 2023;138:106316.
    PubMed     Abstract available


  367. PELLET A, Bertolus C, Saintigny P, Foy JP, et al
    Reliability of gene-expression profiling from tumor biopsy for refining neoadjuvant strategies in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2023;138:106310.
    PubMed     Abstract available


  368. ROBBINS Y, Friedman J, Redman J, Sievers C, et al
    Tumor cell HLA class I expression and pathologic response following neoadjuvant immunotherapy for newly diagnosed head and neck cancer.
    Oral Oncol. 2023;138:106309.
    PubMed     Abstract available


  369. WINNAND P, Ooms M, Heitzer M, Lammert M, et al
    Real-time detection of bone-invasive oral cancer with laser-induced breakdown spectroscopy: A proof-of-principle study.
    Oral Oncol. 2023;138:106308.
    PubMed     Abstract available


  370. WU Z, Han Y, Wan Y, Hua X, et al
    Oral microbiome and risk of incident head and neck cancer: A nested case-control study.
    Oral Oncol. 2023;137:106305.
    PubMed     Abstract available


  371. ARGYRIS PP, Saavedra F, Malz C, Stone IA, et al
    Intracellular calprotectin (S100A8/A9) facilitates DNA damage responses and promotes apoptosis in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;137:106304.
    PubMed     Abstract available


  372. YEO BSY, Song HJJMD, Soong YL, Chua MLK, et al
    Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis.
    Oral Oncol. 2023;136:106242.
    PubMed     Abstract available


  373. ADEOYE J, Zheng LW, Thomson P, Choi SW, et al
    Explainable ensemble learning model improves identification of candidates for oral cancer screening.
    Oral Oncol. 2023;136:106278.
    PubMed     Abstract available


    December 2022
  374. IDA S, Takahashi H, Tada H, Mito I, et al
    Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2022;137:106296.
    PubMed     Abstract available


  375. GHEENA S, Ezhilarasan D
    Personalized mRNA cancer vaccines with immune checkpoint inhibitors: A promising therapeutic approach in oral cancer patients.
    Oral Oncol. 2022;137:106282.
    PubMed    


  376. DE FELICE F, Bossi P
    Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Hypothesis coming from the subgroup analysis.
    Oral Oncol. 2022;137:106275.
    PubMed    


  377. PERES MA, Huihua L, Antunes JLF, Perea LME, et al
    Time trend and Age-Period-Cohort analysis of potentially HPV-related oral and pharyngeal cancer incidence in Singapore between 1968 and 2017.
    Oral Oncol. 2022;136:106272.
    PubMed     Abstract available


  378. TAZEEN S, Suri H, Lakshmi R, Subash A, et al
    Swallowing: A delayed milestone post-surgery in tongue cancers.
    Oral Oncol. 2022;135:106238.
    PubMed     Abstract available


  379. TAVERNA F, Alfieri S, Rebecca R, Giulia C, et al
    Comparing BamHI-W and CE-marked assays to detect circulating Epstein-Barr Virus (EBV) DNA of nasopharyngeal cancer patients in a non-endemic area.
    Oral Oncol. 2022;135:106229.
    PubMed     Abstract available


  380. GUNAWARDENA DA, Howes D, Fleming S, Clark J, et al
    Reconstruction of a maxillectomy and rhinectomy defect utilising a novel subperiosteal prosthesis and magnet-retained nasal prosthesis: A case report.
    Oral Oncol. 2022;135:106222.
    PubMed    


  381. TAPIA M, Manji J, Dhillon K, Kleid S, et al
    The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection.
    Oral Oncol. 2022;135:106213.
    PubMed     Abstract available


    November 2022
  382. MITO I, Takahashi H, Kawabata-Iwakawa R, Horikawa M, et al
    Tumor-derived exosomes elicit cancer-associated fibroblasts shaping inflammatory tumor microenvironment in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;136:106270.
    PubMed     Abstract available


  383. KIRAN NAZEER P, Shaheen S, Shafique K, Sarfraz A, et al
    The role of precision medicine in head and neck cancer: A systematic study of ongoing clinical trials.
    Oral Oncol. 2022;136:106271.
    PubMed    


  384. PENG Y, Liu Y, Shen G, Chen Z, et al
    Improved accuracy of auto-segmentation of organs at risk in radiotherapy planning for nasopharyngeal carcinoma based on fully convolutional neural network deep learning.
    Oral Oncol. 2022;136:106261.
    PubMed     Abstract available


  385. MANZOOR H, Rasheed A, Zeen F, Sarfraz A, et al
    Anti-PD-1 immunotherapy - Pembrolizumab current clinical trials for advanced head and neck cancer: A mapping systematic study.
    Oral Oncol. 2022;136:106266.
    PubMed    


  386. LIU HC, Williamson CW, Zou J, Todd JR, et al
    Quantitative prediction of aspiration risk in head and neck cancer patients treated with radiation therapy.
    Oral Oncol. 2022;136:106247.
    PubMed     Abstract available


  387. CHAN JYK, Cheung MK, Lan L, Ng C, et al
    Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes.
    Oral Oncol. 2022;135:106245.
    PubMed     Abstract available


  388. KMIECIK M, Nogal P, Banaszewski J, Wierzbicka M, et al
    Corrigendum to "Anterolateral thigh free flap reconstruction of pharyngoesophageal defect caused by radiotherapy for laryngeal cancer: A case report" [Oral Oncol. 134 (2022) 106135].
    Oral Oncol. 2022 Nov 4:106233. doi: 10.1016/j.oraloncology.2022.106233.
    PubMed    


  389. QUAN T, Guan W, Huang W, Cui C, et al
    Carotid space involvement is a prognostic factor and marker for induction chemotherapy in patients with nasopharyngeal carcinoma.
    Oral Oncol. 2022;135:106230.
    PubMed     Abstract available


  390. BISHESHAR SK, van der Kamp MF, de Ruiter EJ, Ruiter LN, et al
    The prognostic role of tumor associated macrophages in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis.
    Oral Oncol. 2022;135:106227.
    PubMed     Abstract available


  391. CHIDAMBARAM S, Hong SA, Simpson MC, Osazuwa-Peters N, et al
    Temporal trends in oropharyngeal cancer incidence, survival, and cancer-directed surgery among elderly Americans.
    Oral Oncol. 2022;134:106132.
    PubMed     Abstract available


  392. AROSIO AD, Bernasconi DP, Valsecchi MG, Pacifico C, et al
    Patterns of recurrences in sinonasal cancers undergoing an endoscopic surgery-based treatment: Results of the MUSES* on 940 patients: *MUlti-institutional collaborative Study on Endoscopically treated Sinonasal cancers.
    Oral Oncol. 2022;134:106123.
    PubMed     Abstract available


  393. MANJUSHA M, Saravanan M
    Oropharyngeal cancer associated with sarcopenic obesity and sarcopenic weight loss.
    Oral Oncol. 2022;134:106101.
    PubMed    


  394. FITZGERALD CWR, Davies JC, de Almeida JR, Rich JT, et al
    Factors predicting pharyngocutaneous fistula in patients after salvage laryngectomy for laryngeal malignancy - A multicenter collaborative cohort study.
    Oral Oncol. 2022;134:106089.
    PubMed     Abstract available


  395. DE LUCA P, Scarpa A, Viola P, Motta G, et al
    Collision tumors of the larynx: A retrospective single-center case series of an extremely rare phenomenon.
    Oral Oncol. 2022;134:106096.
    PubMed    


  396. WEINBERGER JM, Abd El Qadir N, Hirshoren N
    Double trouble: A cohort study of re-irradiation and laryngectomy - Severity of and risk for pharyngocutaneous fistula.
    Oral Oncol. 2022;134:106069.
    PubMed     Abstract available


  397. DE BREE R, Leemans CR
    When to perform a paratracheal lymph node dissection during total laryngectomy?
    Oral Oncol. 2022;134:106048.
    PubMed    


  398. WU B, Shen L, Peng G, Li Y, et al
    Molecular characteristics of pediatric nasopharyngeal carcinoma using whole-exome sequencing.
    Oral Oncol. 2022;135:106218.
    PubMed     Abstract available


  399. HUANG J, Harris E, Lorch J
    Vaccination as a therapeutic strategy for Nasopharyngeal carcinoma.
    Oral Oncol. 2022;135:106083.
    PubMed     Abstract available


    October 2022
  400. XUE S, Song G, Zhu Y, Zhang N, et al
    The efficacy and safety of VEGF/VEGFR inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A meta-analysis.
    Oral Oncol. 2022;135:106231.
    PubMed     Abstract available


  401. KAO DD, Ferrandino RM, Bauml JM, Marshall DC, et al
    Prophylactic feeding tube placement for squamous cell carcinoma of the head and neck.
    Oral Oncol. 2022;135:106216.
    PubMed     Abstract available


  402. ZHU L, Li M, Tang G, Shi L, et al
    Role of salivary miRNAs as noninvasive biomarkers in head and neck squamous cell carcinomas and oral potentially malignant disorders - Reply.
    Oral Oncol. 2022;135:106224.
    PubMed    


  403. DENNIS MJ, Sacco AG, Qi Y, Bykowski J, et al
    A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2022;135:106219.
    PubMed     Abstract available


  404. GOVINDARASU M, Prathap L, Govindasamy R
    Histone deacetylase inhibitors regulate the oral cancer via PI3K/AKT signaling pathway.
    Oral Oncol. 2022;135:106221.
    PubMed    


  405. CHABRILLAC E, Lebars S, Breuskin I, Thariat J, et al
    Pregnancy-associated head and neck cancer:a partnership between theCORASSO patient association and theREFCOR physician networkto study a pathology of extremely rare occurrence.
    Oral Oncol. 2022;135:106223.
    PubMed    


  406. OLAWUNI FO, Sauer AB, Daher GS, Douse DM, et al
    The reporting and representation of sex and gender in head and neck cancer clinical trials.
    Oral Oncol. 2022;135:106217.
    PubMed    


  407. SUNDRAMOORTHY AK, Atchudan R, Arya S
    Utilization of Raman spectroscopy in biochemical fingerprint analysis for oral cancer screening and diagnosis.
    Oral Oncol. 2022;135:106192.
    PubMed    


  408. ZHU L, Deng Y, Ji T, Zhou H, et al
    Metformin and oral cancer: In reply with emphasis on an emerging role of an old drug in oral cancer chemoprevention.
    Oral Oncol. 2022;135:106196.
    PubMed    


  409. MANJUSHA M, Saravanan M
    Development of novel electrochemical based nano-biosensors for the diagnosis of oral potentially malignant disorders and oral carcinoma.
    Oral Oncol. 2022;135:106197.
    PubMed    


  410. SEKAR AA, Veeraraghavan VP, Raj AT, Patil S, et al
    Unravelling the long non-coding RNA, CYTOR can serve as a potential therapeutic target in oral cancer.
    Oral Oncol. 2022;135:106195.
    PubMed    


  411. GURMEET SINGH A, Sathe P, Roy S, Thiagrajan S, et al
    Incidence and impact of skip metastasis in the neck in early oral cancer: Reality or a myth?
    Oral Oncol. 2022;135:106201.
    PubMed     Abstract available


  412. KRISHNAMOORTHY K, Priya Veeraraghavan V, Jayaraman S
    E3 ubiquitin ligases: A therapeutic drug target in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;135:106193.
    PubMed    


  413. ZHU S, Zhang F, Zhao G, Zhang X, et al
    Trends in the global burden of oral cancer joint with attributable risk factors: Results from the global burden of disease study 2019.
    Oral Oncol. 2022;134:106189.
    PubMed     Abstract available


  414. LIU W, Ji T, Zhang C, Zhou Q, et al
    Cell-free DNA hypermethylated genes may have a limited role in cancer screening but a potential role in risk assessment of head and neck cancer.
    Oral Oncol. 2022;134:106129.
    PubMed     Abstract available


  415. HENG Y, Yang Z, Lin J, Liu Q, et al
    Risks of central lymph node metastasis in papillary thyroid carcinoma with or without multifocality in at least one lobe: A multi-center analysis.
    Oral Oncol. 2022;134:106185.
    PubMed     Abstract available


    September 2022
  416. MORSE RT, Beaty B, Scanga L, Blumberg J, et al
    Diagnostic accuracy of FNA to determine HPV status in HPV-associated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;134:106131.
    PubMed     Abstract available


  417. ZHU GL, Fang XL, Yang KB, Tang LL, et al
    Development and validation of a joint model for dynamic prediction of overall survival in nasopharyngeal carcinoma based on longitudinal post-treatment plasma cell-free Epstein-Barr virus DNA load.
    Oral Oncol. 2022;134:106140.
    PubMed     Abstract available


  418. XUE F, Ou D, Ou X, Zhou X, et al
    Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2022;134:106139.
    PubMed     Abstract available


  419. SANKAR S
    New insights into CAR T-cell therapy for recurrent head and neck squamous cell carcinoma.
    Oral Oncol. 2022;134:106137.
    PubMed    


  420. KMIECIK M, Nogal P, Wierzbicka M, Jackowska J, et al
    Anterolateral thigh free flap reconstruction of pharyngoesophageal defect caused by radiotherapy for laryngeal cancer: A case report.
    Oral Oncol. 2022;134:106135.
    PubMed     Abstract available


  421. GUPTA T, Kannan S, Ghosh-Laskar S, Agarwal JP, et al
    Concurrent chemoradiotherapy with cisplatin given once-a-week versus every-three weekly in head and neck squamous cell carcinoma: Non-inferior, equivalent, or superior?
    Oral Oncol. 2022;134:106130.
    PubMed     Abstract available


  422. HITT R, Mesia R, Lozano A, Iglesias Docampo L, et al
    Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
    Oral Oncol. 2022;134:106087.
    PubMed     Abstract available


  423. ZHANG J, Wu HY, Lu Q, Shan XF, et al
    Effects of personalized swallowing rehabilitation in patients with oral cancer after free flap transplantation: A cluster randomized controlled trial.
    Oral Oncol. 2022;134:106097.
    PubMed     Abstract available


  424. PATIL V, Kumar S, Noronha V, Menon N, et al
    Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.
    Oral Oncol. 2022;134:106085.
    PubMed    


  425. SARODE GS, Anand R, Sharma NK, Sarode SC, et al
    Hot and cold tumor: Recent developments and perspectives on oral cancer.
    Oral Oncol. 2022;134:106114.
    PubMed    


  426. BEOM HEO D, Piao Y, Hee Lee J, Ju SH, et al
    Completion thyroidectomy may not be required for papillary thyroid carcinoma with multifocality, lymphovascular invasion, extrathyroidal extension to the strap muscles, or five or more central lymph node micrometastasis.
    Oral Oncol. 2022;134:106115.
    PubMed     Abstract available


  427. SAHNI V, Kumar A, Gupta S, Sharma S, et al
    Metformin and oral cancer.
    Oral Oncol. 2022;134:106125.
    PubMed    


  428. TOBIAS MAS, Nogueira BP, Santana MCS, Pires RG, et al
    Artificial intelligence for oral cancer diagnosis: What are the possibilities?
    Oral Oncol. 2022;134:106117.
    PubMed     Abstract available


  429. SHREE HARINI K, Ezhilarasan D, Elumalai P
    Restoring the anti-tumor property of PTEN: A promising oral cancer treatment.
    Oral Oncol. 2022;134:106113.
    PubMed    


  430. NONG T, Medrano T, Marrero C, Rubens M, et al
    Radiation induced taste changes in head and neck cancer - differential impact of treatment factors.
    Oral Oncol. 2022;134:106105.
    PubMed    


  431. MUTHUKRISHNAN L
    "TGM3 - A novel biomarker as a potential diagnostic target for head and neck squamous cell carcinoma (HNSCC)".
    Oral Oncol. 2022;134:106118.
    PubMed    


  432. MONY U, Priya Veeraraghavan V
    "Rules" to the genetic progression of tumours deciphered: Is it time to think differently in treating oral cancer patients?
    Oral Oncol. 2022;134:106111.
    PubMed    


  433. PRASAD M, Jayaraman S, Rajagopal P, Veeraraghavan VP, et al
    Apoptosis regulating CircRNAs: Emerging role in oral cancer therapeutics.
    Oral Oncol. 2022;134:106107.
    PubMed    


  434. DE WIT JG, van Schaik JE, Voskuil FJ, Vonk J, et al
    Comparison of narrow band and fluorescence molecular imaging to improve intraoperative tumour margin assessment in oral cancer surgery.
    Oral Oncol. 2022;134:106099.
    PubMed     Abstract available


  435. VILASECA I, Xavier Aviles-Jurado F, Lehrer E, Valduvieco I, et al
    CO2-TOLMS for laryngeal cancer in the elderly, pushing the boundaries of partial laryngectomy.
    Oral Oncol. 2022;134:106088.
    PubMed     Abstract available


  436. YUAN H, Yan M, Liang X, Liu W, et al
    Decoding the associations between cell functional states in head and neck cancer based on single-cell transcriptome.
    Oral Oncol. 2022;134:106110.
    PubMed     Abstract available


  437. BALACHANDER K, Vijayashree Priyadharsini J, Paramasivam A
    Advances in oral cancer early diagnosis and treatment strategies with liquid biopsy-based approaches.
    Oral Oncol. 2022;134:106108.
    PubMed    


  438. TAKENAKA Y, Takemoto N, Otsuka T, Nishio M, et al
    Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: A multicenter retrospective study.
    Oral Oncol. 2022;132:106018.
    PubMed     Abstract available


  439. CHABRILLAC E, Jackson R, Mattei P, D'Andrea G, et al
    Paratracheal lymph node dissection during total (pharyngo-)laryngectomy: A systematic review and meta-analysis.
    Oral Oncol. 2022;132:106017.
    PubMed     Abstract available


  440. DENG W, Zhao G, Li Z, Yang L, et al
    Recovery pattern analysis of swallowing function in patients undergoing total glossectomy and hemiglossectomy.
    Oral Oncol. 2022;132:105981.
    PubMed     Abstract available


    August 2022
  441. CHANDRALEKHA SELVAKUMAR S, Auxzilia Preethi K, Sekar D
    Non-coding RNAs influencing anti PD-1 immunotherapy in head and neck squamous cell carcinoma (HNSCC).
    Oral Oncol. 2022;134:106092.
    PubMed    


  442. YADALAM PK, Anegundi RV, Ramadoss R, Joseph B, et al
    Felodipine repurposed for targeting TRPV1 receptor to relieve oral cancer pain.
    Oral Oncol. 2022;134:106094.
    PubMed    


  443. SEMPRINI J
    Oral cancer screening prevalence in low-income adults before and after the ACA.
    Oral Oncol. 2022;134:106055.
    PubMed     Abstract available


  444. PAZHANI J, Veeraraghavan VP, Jayaraman S
    Aurora kinase in oral cancer: A potential therapeutic target to improve treatment efficiency.
    Oral Oncol. 2022;134:106093.
    PubMed    


  445. KRUTZ M, Acharya P, Chissoe G, Raj V, et al
    Tobacco cessation after head and neck cancer diagnosis is an independent predictor of treatment response and long-term survival.
    Oral Oncol. 2022;134:106072.
    PubMed     Abstract available


  446. HEMPENIUS MA, Bisheshar SK, Slagter-Menkema L, van der Kamp MF, et al
    Inter-assay reliability of programmed cell death-ligand 1 in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;134:106086.
    PubMed     Abstract available


  447. VAISH R, Mittal N, Mahajan A, Rane SU, et al
    Sentinel node biopsy in node negative early oral cancers: Solution to the conundrum!
    Oral Oncol. 2022;134:106070.
    PubMed     Abstract available


  448. MUTHUPANDIAN S, Muralidharan M, Madhavan Y, Hariharan NM, et al
    Prospective role of salivary MicroRNA for early detection - personalized therapy of head and neck squamous cell carcinoma.
    Oral Oncol. 2022;134:106063.
    PubMed    


  449. PARAMASIVAM A
    Circulating circular RNAs: Novel potential biomarkers and therapeutic targets for oral cancer.
    Oral Oncol. 2022;134:106067.
    PubMed    


  450. EZHILARASAN D, Shree Harini K
    Novel mTOR inhibitors: Promising therapeutic interventions in oral cancer therapy.
    Oral Oncol. 2022;133:106066.
    PubMed    


  451. PRASAD M, Veeraraghavan VP, Jayaraman S
    Tumorigenic potential of GLUT4: A therapeutic target for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;133:106061.
    PubMed    


  452. YU C, Zhou Z
    Relationship between young non-smokers and oral cancer: What can we learn?
    Oral Oncol. 2022;133:106064.
    PubMed    


  453. REKHA K, Venkidasamy B, Govindasamy R, Neralla M, et al
    Isothiocyanates (AITC & BITC) bioactive molecules: Therapeutic potential for oral cancer.
    Oral Oncol. 2022;133:106060.
    PubMed    


  454. BALACHANDER K, Abilasha R, Priyadharsini JV, Balamurugan R, et al
    Targeting mitochondria for apoptosis in oral cancer: Therapeutic potential and obstacles.
    Oral Oncol. 2022;133:106059.
    PubMed    


  455. SARODE GS, Kumari N, Gophane R, Ghone U, et al
    Trends and prospects in oral cancer vaccine.
    Oral Oncol. 2022;133:106051.
    PubMed    


  456. MA SJ, Yu H, Khan M, Yu B, et al
    Defining the optimal threshold and prognostic utility of pre-treatment hemoglobin level as a biomarker for survival outcomes in head and neck cancer patients receiving chemoradiation.
    Oral Oncol. 2022;133:106054.
    PubMed     Abstract available


  457. VERDONCK-DE LEEUW I, Dawson C, Licitra L, Eriksen JG, et al
    European Head and Neck Society recommendations for head and neck cancer survivorship care.
    Oral Oncol. 2022;133:106047.
    PubMed     Abstract available


  458. DONA MG, Rollo F, Pichi B, Moretto S, et al
    Updates on Human Papillomavirus-driven oropharyngeal squamous cell carcinomas in a southern European country.
    Oral Oncol. 2022;131:105947.
    PubMed    


    July 2022
  459. DASSE R, Dupin C, Gorphe P, Temam S, et al
    Proposal for an algorithm to avoid neck dissection during salvage total laryngectomy. A GETTEC multicentric study.
    Oral Oncol. 2022;133:106026.
    PubMed     Abstract available


  460. CHOW JCH, Lee AWM, Wong CHL, Ng WT, et al
    Epstein-Barr virus directed screening for nasopharyngeal carcinoma in individuals with positive family history: A systematic review.
    Oral Oncol. 2022;133:106031.
    PubMed     Abstract available


  461. KRISHNAN M, Venkidasamy B
    PEITC: A prospective natural metabolite in oral cancer treatment.
    Oral Oncol. 2022;133:106044.
    PubMed    


  462. YU C, Zhou Z
    Assessment of oral dysfunction after oral cancer treatment.
    Oral Oncol. 2022;133:106046.
    PubMed    


  463. SARODE GS, Sarode SC, Kumari N, Gophane R, et al
    FAP-targeted imaging in oral cancer: Critical viewpoints.
    Oral Oncol. 2022;133:106024.
    PubMed    


  464. YASASVE M, Manjusha M, Saravanan M
    Polymorphism in pro-inflammatory cytokines and their genetic susceptibility towards oral precancerous lesions and oral cancer.
    Oral Oncol. 2022;133:106027.
    PubMed    


  465. KONO M, Saito S, Egloff AM, Allen CT, et al
    The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations.
    Oral Oncol. 2022;132:106012.
    PubMed     Abstract available


  466. MELO G, Silva CAB, Hague A, Parkinson EK, et al
    Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge.
    Oral Oncol. 2022;132:105979.
    PubMed     Abstract available


  467. KUMARESAN V, Sivaperumal P, Smiline Girija AS
    Bispecific antibodies targeting tumor-associated metalloprotease and recruit NK cells - Multifunctional therapeutic approach against oral cancer.
    Oral Oncol. 2022;132:106013.
    PubMed    


  468. HUANG H, Li L, Cao Q, Jiang H, et al
    Choroid plexus papilloma of auditory nerve: A case report.
    Oral Oncol. 2022;132:106009.
    PubMed    


  469. RENU K, Veeraraghavan VP, Raj A T, Patil S, et al
    The peroxisome proliferator-activated receptor-alpha (PPAR-alpha): A new therapeutic target for oral cancer.
    Oral Oncol. 2022;132:106007.
    PubMed    


  470. ALLEN JL, Hames RA, Mastroianni NM, Greenstein AE, et al
    Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Anti-invasive therapeutic in Head and neck squamous cell carcinoma.
    Oral Oncol. 2022;132:106008.
    PubMed     Abstract available


  471. SARODE GS, Kumari N, Sarode SC
    Oral cancer histopathology images and artificial intelligence: A pathologist's perspective.
    Oral Oncol. 2022;132:105999.
    PubMed    


  472. DE VRIES J, Poelman A, Sidorenkov G, Festen S, et al
    The association of frailty and outcomes of geriatric assessment with acute radiation-induced toxicity in patients with head and neck cancer.
    Oral Oncol. 2022;130:105933.
    PubMed     Abstract available


  473. RIBEIRO MFA, Oliveira MCM, Leite AC, Bruzinga FFB, et al
    Assessment of screening programs as a strategy for early detection of oral cancer: a systematic review.
    Oral Oncol. 2022;130:105936.
    PubMed     Abstract available


  474. TANG R, Mao S, Liu S, Li Z, et al
    Types of endoscopic surgical approaches for benign parapharyngeal space tumors.
    Oral Oncol. 2022;130:105875.
    PubMed    


  475. EZHILARASAN D, Shree Harini K, Lakshmi T
    Osteopontin: A reliable diagnostic marker and an attractive therapeutic target in oral cancers.
    Oral Oncol. 2022;132:106005.
    PubMed    


    June 2022
  476. MISRA SR, Das R
    Central oral medicine repository: A proposal to speed up the diagnostic process for oral potentially malignant disorders and oral carcinoma!
    Oral Oncol. 2022;132:105998.
    PubMed    


  477. BALACHANDER K, Paramasivam A
    Anti-PD-1 agent: A promising immunotherapy drug for oral cancer?
    Oral Oncol. 2022;132:105997.
    PubMed    


  478. BABU S, Krishnan M, Priya Veeraraghavan V, Jayaraman S, et al
    Role of salivary miRNAs in the diagnosis and prognosis of head and neck squamous cell carcinoma.
    Oral Oncol. 2022;132:105993.
    PubMed    


  479. ALESSANDRINI L, Ferrari M, Taboni S, Sbaraglia M, et al
    Tumor-stroma ratio, neoangiogenesis and prognosis in laryngeal carcinoma. A pilot study on preoperative biopsies and matched surgical specimens.
    Oral Oncol. 2022;132:105982.
    PubMed     Abstract available


  480. SHREE HARINI K, Ezhilarasan D, Lakshmi T
    Novel fibroblast growth factor receptor inhibitors: Potential therapeutic approach in oral cancer treatment.
    Oral Oncol. 2022;132:105983.
    PubMed    


  481. REVATHI D, Dhanraj G, Ashok V
    Immune check point inhibitors: A promising therapeutic approach in oral cancer.
    Oral Oncol. 2022;132:105977.
    PubMed    


  482. SEKARAN S, Pitchaiah S, Ganapathy D
    Can miR-21 be considered as a potential biomarker and a therapeutic target in oral cancer?
    Oral Oncol. 2022;131:105973.
    PubMed    


  483. ZONG J, Ji P, Lin C, Zhang R, et al
    Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma.
    Oral Oncol. 2022;131:105972.
    PubMed     Abstract available


  484. BALACHANDER K, Paramasivam A
    Ferroptosis: An emerging therapeutic target for oral cancer.
    Oral Oncol. 2022;131:105970.
    PubMed    


  485. GANAPATHY D, Sekaran S, Pitchaiah S
    Is prognostic monitoring of high-risk populations at risk for oral cancer necessary after infection with COVID-19?
    Oral Oncol. 2022;131:105968.
    PubMed    


  486. LUO HD, Xia FJ, Wu JH, Yi B, et al
    Efficacy of chemoradiotherapy in survival of stage nasopharyngeal carcinoma and establishment of a prognostic model.
    Oral Oncol. 2022;131:105927.
    PubMed     Abstract available


  487. SHREE HARINI K, Ezhilarasan D, Lakshmi T
    Patient derived tumour organoids: An emerging strategy in oral cancer research and therapeutics.
    Oral Oncol. 2022;131:105954.
    PubMed    


  488. VARGHESE BT, Nair SP, Janardhan D
    Transglottic intralaryngeal papillary thyroid carcinoma.
    Oral Oncol. 2022;131:105935.
    PubMed     Abstract available


  489. YANG Z, Liao J, Schumaker L, Carter-Cooper B, et al
    Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2022;131:105939.
    PubMed     Abstract available


  490. SHREE HARINI K, Ezhilarasan D
    Promising autophagy inhibitors: Therapeutic implications in oral cancer.
    Oral Oncol. 2022;131:105948.
    PubMed    


  491. DE FELICE F
    FLASH radiotherapy in head and neck cancer: Myth or reality?
    Oral Oncol. 2022;131:105953.
    PubMed    


  492. FERRELI F, Pirola F, Di Santo D, De Virgilio A, et al
    A critical analysis of the classifications of squamous cell carcinoma of the nasal vestibule.
    Oral Oncol. 2022;129:105880.
    PubMed    


    May 2022
  493. JAYARAMAN S, Pazhani J, PriyaVeeraraghavan V, Raj AT, et al
    PCNA and Ki67: Prognostic proliferation markers for oral cancer.
    Oral Oncol. 2022;130:105943.
    PubMed    


  494. BALACHANDER K, Paramasivam A
    Selective autophagy as a potential therapeutic target for oral cancer.
    Oral Oncol. 2022;130:105934.
    PubMed    


  495. PATIL VM, Kolkur M, Kumar Chinthala S, Waratkar G, et al
    Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
    Oral Oncol. 2022;130:105908.
    PubMed    


  496. UEDA Y, Okano S, Enokida T, Fujisawa T, et al
    Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
    Oral Oncol. 2022;130:105932.
    PubMed     Abstract available


  497. WARNER L, O'Hara JT, Lin DJ, Oozeer N, et al
    Transoral robotic surgery and neck dissection alone for head and neck squamous cell carcinoma: Influence of resection margins on oncological outcomes.
    Oral Oncol. 2022;130:105909.
    PubMed     Abstract available


  498. VARGHESE BT, Shivanesan P
    Anatomical distortion of the right recurrent laryngeal nerve in level 7 neck dissection.
    Oral Oncol. 2022;130:105929.
    PubMed    


  499. SMILINE GIRIJA AS
    Natural "epidrugs" and the need of basket trials in the treatment of oral cancer in India.
    Oral Oncol. 2022;130:105931.
    PubMed    


  500. SHIAO JC, Holt D, Ladbury C, Gao D, et al
    The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;130:105907.
    PubMed     Abstract available


  501. LOW SK, Reed CT, Millo C, Turkbey EB, et al
    Cecal mass: An unusual site of metastasis from HPV-associated oropharyngeal cancer.
    Oral Oncol. 2022;130:105928.
    PubMed    


  502. PARAMASIVAM A
    Plasma circulating tumor DNA as a molecular marker for oral cancer.
    Oral Oncol. 2022;130:105926.
    PubMed    


  503. SELVARAJ J, Yasothkumar D, Vishnu Priya V, Raj AT, et al
    Development and tumorigenic potential of TP53: A therapeutic target for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;130:105922.
    PubMed    


  504. YANG X, Song H, Ji T, Du G, et al
    The implications of gene mutations in salivary DNA for noninvasive diagnosis of head and neck cancer with a focus on oral cancer.
    Oral Oncol. 2022;130:105924.
    PubMed     Abstract available


  505. FORNER D, Mok F, Verma N, Karam I, et al
    Placement technique impacts gastrostomy tube-related complications amongst head and neck cancer patients.
    Oral Oncol. 2022;130:105903.
    PubMed     Abstract available


  506. PAZHANI J, Jayaraman S, Veeraraghavan VP, Somasundaram DB, et al
    Targeting cancer associated fibroblasts - A TGF-beta based immunotherapy for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;130:105899.
    PubMed    


  507. JIANG Y, Yang S, Qi Y
    Comment on: The prognostic value of radiologic extranodal extension in nasopharyngeal carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2022;130:105872.
    PubMed    


  508. MADY LJ, Baddour K, Hodges JC, Magana LC, et al
    Corrigendum to "The impact of frailty on mortality in non-surgical head and neck cancer treatment: Shifting the clinical paradigm" [Oral Oncol. 126 (2022) 105766].
    Oral Oncol. 2022 May 2:105882. doi: 10.1016/j.oraloncology.2022.105882.
    PubMed    


  509. SWARTZ JE, Smits HJG, Philippens MEP, de Bree R, et al
    Correlation and colocalization of HIF-1alpha and pimonidazole staining for hypoxia in laryngeal squamous cell carcinomas: A digital, single-cell-based analysis.
    Oral Oncol. 2022;128:105862.
    PubMed     Abstract available


  510. YEOM S, Jung EK, Lee DH, Lee JK, et al
    Clinical features and recurrence factors of benign neoplasms of the tongue base.
    Oral Oncol. 2022;128:105866.
    PubMed     Abstract available


  511. MULLER RG, Hamill CS, Vu B, Thuener J, et al
    Impact of AJCC 8th edition staging system and definitive treatment choice on the prognosis of complete responders with p16+ and p16- oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2022;128:105861.
    PubMed     Abstract available


    April 2022
  512. GALLOGLY JA JR, Weber AK, Mazul AL, Brinkmeier JV, et al
    Inferior outcomes associated with emergency department presentation for head and neck cancer surgery.
    Oral Oncol. 2022;129:105894.
    PubMed     Abstract available


  513. SHE L, Tian K, Han J, Zuo W, et al
    Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
    Oral Oncol. 2022;129:105871.
    PubMed     Abstract available


  514. KATO A, Matsuda Y, Morioka R, Okui T, et al
    Discrepancy between subjective and objective postoperative oral dysfunction assessment after oral cancer treatment: A single-center cross-sectional study.
    Oral Oncol. 2022;129:105879.
    PubMed     Abstract available


  515. HAIST C, Poschinski Z, Bister A, Hoffmann MJ, et al
    Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas.
    Oral Oncol. 2022;129:105867.
    PubMed     Abstract available


  516. SEKAR D, Panagal M, Manimaran D, Ahmad N, et al
    miR-185 and its anti-miR as a biomarker and therapeutic target for oral cancer.
    Oral Oncol. 2022;129:105873.
    PubMed    


  517. LIU T, Ma L, Song L, Yan B, et al
    CENPM upregulation by E5 oncoprotein of human papillomavirus promotes radiosensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;129:105858.
    PubMed     Abstract available


  518. NERALLA M, Senthilnthan P, Kubendiran D, Nandan A, et al
    Dry needle therapy for post operative shoulder dysfunction in oral cancer patients.
    Oral Oncol. 2022;128:105865.
    PubMed    


  519. PETRELLI F, Trevisan F, Ghidini A, Capriotti V, et al
    Comparison of platinum-based regimens in combination with radiotherapy for head and neck cancers: A network meta-analysis.
    Oral Oncol. 2022;128:105864.
    PubMed    


  520. ZHOU S, Chan C, Rulach R, Dyab H, et al
    Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection.
    Oral Oncol. 2022;128:105870.
    PubMed     Abstract available


  521. YANG ZC, Nie ZQ, Chen QY, Du CC, et al
    Cost-Effectiveness analysis of combining plasma Epstein-Barr virus DNA testing and different surveillance imaging modalities for nasopharyngeal carcinoma patients in first remission.
    Oral Oncol. 2022;128:105851.
    PubMed     Abstract available


  522. FENG G, Feng H, Qi Y, Wang T, et al
    Interaction analysis between germline genetic variants and somatic mutations in head and neck cancer.
    Oral Oncol. 2022;128:105859.
    PubMed     Abstract available


  523. CHEN Y, Zheng X, Lin J, Gao X, et al
    A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
    Oral Oncol. 2022;128:105860.
    PubMed     Abstract available


  524. TIAN K, Han J, Wang Z, Chen J, et al
    Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
    Oral Oncol. 2022;128:105842.
    PubMed     Abstract available


  525. BALACHANDER K, Roy A, Priyadharsini JV, Murugan S, et al
    Mitochondrial DNA in circulating exosomes: A novel biomarker and potential therapeutic target for oral cancer.
    Oral Oncol. 2022;128:105857.
    PubMed    


  526. DE LA COUR CD, Munk C, Aalborg GL, Kjaer SK, et al
    Base of tongue/tonsillar and laryngeal cancer in Denmark 1994-2018: Temporal trends in incidence according to education and age.
    Oral Oncol. 2022;128:105832.
    PubMed     Abstract available


  527. BANERJEE A, Misra SR, Roy B, Singh S, et al
    Central oral histopathology registry (COHR) - A proposal promising hope for oral cancer and oral pathology research.
    Oral Oncol. 2022;128:105856.
    PubMed    


  528. SEKAR D, Murthykumar K, Ganapathy D
    miR-206 and its mimics: A predictive biomarker and therapeutic molecule in the treatment of oral cancer.
    Oral Oncol. 2022;128:105849.
    PubMed    


  529. RISCHIN D, Harrington KJ, Greil R, Soulieres D, et al
    Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
    Oral Oncol. 2022;128:105815.
    PubMed     Abstract available


  530. TANS L, Al-Mamgani A, Kwa SLS, Elbers JBW, et al
    Single vocal cord irradiation for early-stage glottic cancer: Excellent local control and favorable toxicity profile.
    Oral Oncol. 2022;127:105782.
    PubMed     Abstract available


  531. DODDAWAD VG, Premalatha BR, Sreeshyla HS, Nitin P, et al
    Classification staging systems on clinical and radiographic features of inverted sinonasal papilloma: A case report.
    Oral Oncol. 2022;127:105768.
    PubMed     Abstract available


    March 2022
  532. PATIL V, Noronha V, Joshi A, Menon N, et al
    RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation.
    Oral Oncol. 2022;128:105816.
    PubMed     Abstract available


  533. CHANG CT, Liu SP, Muo CH, Liao YF, et al
    The impact of dental therapy timelines and irradiation dosages on osteoradionecrosis in oral cancer patients: A population-based cohort study.
    Oral Oncol. 2022;128:105827.
    PubMed     Abstract available


  534. HSIEH MC, Wang CC, Yang CC, Lien CF, et al
    The role of induction chemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A nationwide population-based matched study.
    Oral Oncol. 2022;128:105848.
    PubMed     Abstract available


  535. YANG X, Xu X, Zhang C, Ji T, et al
    The diagnostic value and prospects of gene mutations in circulating tumor DNA for head and neck cancer monitoring.
    Oral Oncol. 2022;128:105846.
    PubMed     Abstract available


  536. RANJAN MISRA S, Das R
    Tele-screening for early detection of oral cancer during the COVID-19 pandemic era: Diagnostic pitfalls and potential misinterpretations!
    Oral Oncol. 2022;128:105845.
    PubMed    


  537. MATTOX AK, D'Souza G, Khan Z, Allen H, et al
    Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer.
    Oral Oncol. 2022;128:105805.
    PubMed     Abstract available


  538. BALACHANDER K, Paramasivam A
    Cell-free mitochondrial DNA as a novel non-invasive biomarker for oral cancer.
    Oral Oncol. 2022;127:105825.
    PubMed    


  539. YAMAGUMA Y, Kaneuji T, Shirouzu S, Fukui T, et al
    Combination therapy of Mohs paste and chemotherapy improved metastatic oral cancer to the precordium skin and bilateral axillary lymph nodes: A case report.
    Oral Oncol. 2022;127:105817.
    PubMed     Abstract available


  540. VILLARD A, Breuskin I, Casiraghi O, Asmandar S, et al
    Confocal laser endomicroscopy and confocal microscopy for head and neck cancer imaging: Recent updates and future perspectives.
    Oral Oncol. 2022;127:105826.
    PubMed     Abstract available


  541. PATIL V, Alone M, Rai R, Noronha V, et al
    Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers.
    Oral Oncol. 2022;127:105824.
    PubMed    


  542. DE LUCA P, Di Stadio A, Tassone D, de Campora L, et al
    Large cervical mass and head and neck cancer. First report of ectopic papillary adenoma of the lung.
    Oral Oncol. 2022;127:105823.
    PubMed     Abstract available


  543. DEVARAJA K, Kabekkodu SP
    Oral microbiome; a potential game-changer in the management of oral cancer?
    Oral Oncol. 2022;127:105822.
    PubMed    


  544. BONETTI VALENTE V, Mantovan Mazzon B, Urbano Collado F, Conrado Neto S, et al
    Clinicopathological and prognostic profile of non-smoking and non-drinking head and neck cancer patients: a population-based comparative study.
    Oral Oncol. 2022;127:105799.
    PubMed     Abstract available


  545. SHETH S, Gilbert J, Deal AM, Chera B, et al
    Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105807.
    PubMed    


  546. VALERO C, Yuan A, Zanoni DK, Lei E, et al
    Young non-smokers with oral cancer: What are we missing and why?
    Oral Oncol. 2022;127:105803.
    PubMed     Abstract available


  547. ELUMALAI P, Ezhilarasan D, Lakshmi T
    Targeting head and neck cancer epigenetics with CRISPR-dCas9: An emerging therapeutic approach.
    Oral Oncol. 2022;127:105801.
    PubMed    


  548. GLAZAR DJ, Johnson M, Farinhas J, Steuer CE, et al
    Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab.
    Oral Oncol. 2022;127:105787.
    PubMed     Abstract available


  549. ROUTILA J, Qiao X, Weltner J, Rantala JK, et al
    Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105772.
    PubMed     Abstract available


  550. BRODY RM, Shimunov D, Cohen RB, Lin A, et al
    A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers.
    Oral Oncol. 2022;127:105798.
    PubMed     Abstract available


  551. GONCALVES JM, Scarini JF, Gondak R, Altemani A, et al
    Oral involvement of sinonasal undifferentiated carcinoma: A case report and immunohistochemical study of a challenging case.
    Oral Oncol. 2022;126:105779.
    PubMed     Abstract available


  552. SAKTHIVEL P, Raveendran S, Rajeshwari M
    Sinonasal small round blue cell tumors: What the clinician must know!
    Oral Oncol. 2022;126:105735.
    PubMed    


  553. PETRIDES GA, Dunn M, Charters E, Venchiarutti R, et al
    Health-related quality of life in maxillectomy patients undergoing dentoalveolar rehabilitation.
    Oral Oncol. 2022;126:105757.
    PubMed     Abstract available


    February 2022
  554. QURESHI HA, Zhu X, Yang GH, Steadele M, et al
    Impact of HPV status on immune responses in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105774.
    PubMed     Abstract available


  555. BELGIOIA L, Becherini C, Bacigalupo A, Bonomo P, et al
    Chemo- immunotherapy and radiation in locally advanced head and neck cancer: Where do we stand?
    Oral Oncol. 2022;127:105773.
    PubMed     Abstract available


  556. DAGLINAMRATA, Lakshmi T, Rushabh D, Dineshkumar T, et al
    Telescreening as an alternate modality for early detection of oral cancer.
    Oral Oncol. 2022;127:105785.
    PubMed    


  557. HARING CT, Dermody SM, Yalamanchi P, Kang SY, et al
    The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;126:105776.
    PubMed     Abstract available


  558. MICHMERHUIZEN NL, Heenan C, Wang J, Leonard E, et al
    Combined Pik3ca-H1047R and loss-of-function Notch1 alleles decrease survival time in a 4-nitroquinoline N-oxide-driven head and neck squamous cell carcinoma model.
    Oral Oncol. 2022;126:105770.
    PubMed    


  559. MADY LJ, Baddour K, Hodges JC, Magana LC, et al
    The impact of frailty on mortality in non-surgical head and neck cancer treatment: Shifting the clinical paradigm.
    Oral Oncol. 2022;126:105766.
    PubMed     Abstract available


  560. ZHANG S, Zhang W, Zhang J
    Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;126:105755.
    PubMed     Abstract available


  561. LI JL, Hsieh TL, Ou MC, Lin FC, et al
    Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients.
    Oral Oncol. 2022;126:105729.
    PubMed    


  562. LENOCI D, Carenzo A, Cavalieri S, Pistore F, et al
    Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials.
    Oral Oncol. 2022;126:105756.
    PubMed    


  563. CHAN SK, Lin C, Huang SH, Chau TC, et al
    Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2022;126:105736.
    PubMed     Abstract available


  564. SILVERMAN DA, Parikh AS, Liu K, Zhan KY, et al
    Predictors of survival following carotid blowout syndrome.
    Oral Oncol. 2022;125:105723.
    PubMed     Abstract available


  565. CHIN O, Alshafai L, O'Sullivan B, Su J, et al
    Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma.
    Oral Oncol. 2022;125:105716.
    PubMed     Abstract available


  566. CHEN TC, Wang C, Su LY, Lin MC, et al
    Impact of invasion into cervical esophagus for patients with hypopharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;125:105683.
    PubMed     Abstract available


    January 2022
  567. SENGUPTA N, Sarode SC, Sarode GS, Ghone U, et al
    Scarcity of publicly available oral cancer image datasets for machine learning research.
    Oral Oncol. 2022;126:105737.
    PubMed     Abstract available


  568. JONAS H, Simnica D, Bussmann L, Zech H, et al
    Early relapse detection by monitoring of circulating cell-free DNA in patients with localized head and neck squamous cell carcinoma: A subgroup analysis of the multicenter randomized clinical trial IMSTAR-HN.
    Oral Oncol. 2022;126:105733.
    PubMed    


  569. SEKAR D
    Inhibition of OSCC derived ExomiRs and its therapeutic applications in oral cancer.
    Oral Oncol. 2022;126:105747.
    PubMed    


  570. FERRAZZO KL
    Regarding: "Clinical practice guidelines for dental management prior to radiation for head and neck cancer".
    Oral Oncol. 2022;126:105731.
    PubMed    


  571. WARD MC, Miller JA, Walker GV, Moeller BJ, et al
    The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: A simulation.
    Oral Oncol. 2022;126:105721.
    PubMed     Abstract available


  572. LIU X, Li WF, Ding C, Chen L, et al
    Differential benefit of induction chemotherapy according to body mass index in nasopharyngeal carcinoma - Pooled analysis of two randomized trials.
    Oral Oncol. 2022;125:105718.
    PubMed     Abstract available


  573. K AP, Selvakumar SC, Selvaraj J, Mony U, et al
    Reviewing the potential application of miR-21 inhibitors in oral cancer therapeutics.
    Oral Oncol. 2022;125:105713.
    PubMed    


  574. ECONOMOPOULOU P, Kotsantis I, Psyrri A
    Radiotherapy and immunotherapy combination in head and neck cancer: Does current failure qualify as an ending or is it a key to future success?
    Oral Oncol. 2022 Jan 13:105717. doi: 10.1016/j.oraloncology.2022.105717.
    PubMed    


  575. CARDIN GB, Bernard M, Bourbonnais J, Bahig H, et al
    The rs6942067 genotype is associated with a worse overall survival in young or non-smoking HPV-negative patients with positive nodal status in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;125:105696.
    PubMed    


  576. GILLIGAN G, Piemonte E, Lazos J, Panico R, et al
    Chronic wounds of traumatic origin and oral cancer arising de novo: A potential association?
    Oral Oncol. 2022;125:105711.
    PubMed    


  577. PATIL V, Ghandade N, Noronha V, Menon N, et al
    Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes.
    Oral Oncol. 2022;125:105709.
    PubMed    


  578. VIITASALO S, Karhemo PR, Vaananen J, Ilmarinen T, et al
    Exome sequencing reveals candidate mutations implicated in sinonasal carcinoma and malignant transformation of sinonasal inverted papilloma.
    Oral Oncol. 2022;124:105663.
    PubMed     Abstract available


  579. SAKTHIVEL P, Thakar A, Fernandez-Fernandez MM, Panda S, et al
    TransOral UltraSonic surgery (TOUSS) for oral cavity, oropharyngeal and supraglottic malignancy: A prospective study of feasibility, safety, margins, functional and survival outcomes.
    Oral Oncol. 2022;124:105643.
    PubMed     Abstract available


  580. LI MM, Mroz EA, Faquin WC, Lott-Limbach A, et al
    ERalpha: A biomarker and treatment target for oropharyngeal cancer?
    Oral Oncol. 2022;124:105637.
    PubMed    


  581. MALIK A, Panda S, Sakthivel P
    Treatment of early glottic carcinoma: Is it a paradox of choices?
    Oral Oncol. 2022;124:105516.
    PubMed    


  582. ZHANG L, Chen L, Xiao M, Xie X, et al
    Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report.
    Oral Oncol. 2022;124:105466.
    PubMed     Abstract available


    December 2021
  583. COHEN O, Brauer PR, Judson BL, Burtness BA, et al
    Guideline - Adherence in advanced stage head and neck cancer is associated with improved survival - A National study.
    Oral Oncol. 2021;125:105694.
    PubMed     Abstract available


  584. WANG J, Tian Y, Huang H, Huang D, et al
    The prognosis of HPV-associated metastatic pharyngeal patients by primary and distant site.
    Oral Oncol. 2021;125:105675.
    PubMed     Abstract available


  585. SUBASH A, Bylapudi B, Thakur S, Rao VUS, et al
    Oral cancer in India, a growing problem: Is limiting the exposure to avoidable risk factors the only way to reduce the disease burden?
    Oral Oncol. 2021;125:105677.
    PubMed     Abstract available


  586. MERCHANT YP, Mohan M, Shetty S, Bandemegal M, et al
    The submandibular gland in neck dissection: A necessary casualty or a hapless victim?
    Oral Oncol. 2021;125:105678.
    PubMed    


  587. HERNDON P, Jassal JS, Cramer JD
    Association between E-cigarette use and oral HPV-16 infection.
    Oral Oncol. 2021;125:105676.
    PubMed    


  588. DOU Y, Ma C, Wang K, Liu S, et al
    Dysbiotic tumor microbiota associates with head and neck squamous cell carcinoma outcomes.
    Oral Oncol. 2021;124:105657.
    PubMed     Abstract available


  589. NOJI R, Kano Y, Hirai H, Onishi I, et al
    MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma.
    Oral Oncol. 2021;124:105666.
    PubMed     Abstract available


  590. WEI LY, Lin HC, Tsai FC, Ko JY, et al
    Effects of Interleukin-6 on STAT3-regulated signaling in oral cancer and as a prognosticator of patient survival.
    Oral Oncol. 2021;124:105665.
    PubMed     Abstract available


  591. SARI SY, Yilmaz MT, Aktas BY, Aksoy S, et al
    Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: A single-center experience.
    Oral Oncol. 2021;124:105658.
    PubMed     Abstract available


  592. CRAMER JD, Grauer J
    Modeling oral cancer screening in the United States population.
    Oral Oncol. 2021;124:105656.
    PubMed     Abstract available


  593. BIGELOW EO, Windon MJ, Fakhry C, Kiess AP, et al
    Development of a web-based, patient-centered decision aid for oropharyngeal cancer treatment.
    Oral Oncol. 2021;123:105618.
    PubMed     Abstract available


  594. BURNINGHAM K, Moore W, Moon D, Avkshtol V, et al
    Prognostic impact of matted lymphadenopathy in patients with oropharyngeal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Oral Oncol. 2021;123:105623.
    PubMed     Abstract available


    November 2021
  595. GUPTA T, Maheshwari G, Kannan S, Nair S, et al
    Systematic review and meta-analysis of randomized controlled trials comparing elective neck dissection versus sentinel lymph node biopsy in early-stage clinically node-negative oral and/or oropharyngeal squamous cell carcinoma: Evidence-base for pract
    Oral Oncol. 2021;124:105642.
    PubMed     Abstract available


  596. CHAUHAN A, Kaur R, Ghoshal S, Chatterjee D, et al
    Potential prognostic and predictive role of baseline circulating tumor cells in head and neck squamous cell carcinoma.
    Oral Oncol. 2021;124:105636.
    PubMed    


  597. FUEREDER T, Minichsdorfer C, Mittlboeck M, Wagner C, et al
    Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study.
    Oral Oncol. 2021;124:105634.
    PubMed     Abstract available


  598. DENARO N, Merlano M, Garrone O
    In reply to immune desert in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
    Oral Oncol. 2021;124:105640.
    PubMed    


  599. THADURI A, Dungala D, Panuganti A, Majumdar KS, et al
    Addressing the challenges of head and neck cancer care in India - A compelling need of the hour.
    Oral Oncol. 2021;124:105638.
    PubMed    


  600. MADHULAXMI M, Abhinav RP
    Protein changes of WNT signaling pathway in oral cancer.
    Oral Oncol. 2021;123:105624.
    PubMed    


  601. KOWALCHUK RO, Van Abel KM, Yin LX, Garcia J, et al
    Correlation between radiographic and pathologic lymph node involvement and extranodal extension via CT and PET in HPV-associated oropharyngeal cancer.
    Oral Oncol. 2021;123:105625.
    PubMed     Abstract available


  602. GAU M, Fonseca A, Ozsahin M, Fayette J, et al
    Prognostic impact of extranodal extension in resected head and neck squamous cell carcinomas in the era of postoperative chemoradiation: A retrospective monocentric study.
    Oral Oncol. 2021;123:105605.
    PubMed     Abstract available


  603. MISHRA S, Subash A, Rao VUS, Thakur S, et al
    Role of neoadjuvant chemotherapy in head and neck cancer management: A case for exploring diverse treatment strategies for evaluating long-term efficacy.
    Oral Oncol. 2021;123:105594.
    PubMed    


  604. GOLUSINSKI P, Corry J, Poorten VV, Simo R, et al
    De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed?
    Oral Oncol. 2021;123:105620.
    PubMed     Abstract available


  605. WATSON E, Dorna Mojdami Z, Oladega A, Hope A, et al
    Clinical practice guidelines for dental management prior to radiation for head and neck cancer.
    Oral Oncol. 2021;123:105604.
    PubMed     Abstract available


  606. BRIL SI, Chargi N, Wendrich AW, Wegner I, et al
    Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with head and neck cancer.
    Oral Oncol. 2021;123:105617.
    PubMed     Abstract available


  607. WANG Y, Gao Y, Yuan L, Zhang J, et al
    Psychological needs and associated factors among perioperative patients with oral cancer.
    Oral Oncol. 2021;123:105615.
    PubMed    


  608. GRONLUND MP, Jakobsen KK, Mirian C, Gronhoj C, et al
    Nasopharyngeal malignancies in Denmark diagnosed from 1980 to 2014.
    Oral Oncol. 2021;122:105583.
    PubMed     Abstract available


  609. YU J, Tsay C, Sasaki C, Son YH, et al
    Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs.
    Oral Oncol. 2021;122:105585.
    PubMed     Abstract available


  610. SEE A, Chu C, Kiong KL, Teo C, et al
    Surgical salvage of recurrent nasopharyngeal cancer- a multi-institutional review.
    Oral Oncol. 2021;122:105556.
    PubMed    


  611. SAKTHIVEL P, Ramanikanth TV, Thakar A, Singh CA, et al
    TransOral UltraSonic Surgery (TOUSS) assisted supraglottic laryngectomy: Expanding the spectrum of endoscopic head and neck surgeries.
    Oral Oncol. 2021;122:105562.
    PubMed    


  612. THAKAR A, Sakthivel P, Sikka K
    TransOral UltraSonic Surgery (TOUSS) and TransOral Laser (TOL) assisted supraglottic laryngectomy (TOUSS-TOL-SGL): Improvising techniques within the transoral corridor.
    Oral Oncol. 2021;122:105573.
    PubMed    


  613. LIN N, Gao J, Wang H, Zhang H, et al
    Diagnostic value of indocyanine green for sentinel lymph node mapping and lymph node metastasis in oral/oropharyngeal carcinoma.
    Oral Oncol. 2021;122:105563.
    PubMed     Abstract available


  614. RE M, Tomasetti M, Monaco F, Amati M, et al
    NGS-based miRNome identifies miR-449 cluster as marker of malignant transformation of sinonasal inverted papilloma.
    Oral Oncol. 2021;122:105554.
    PubMed     Abstract available


  615. MCDOWELL L, Casswell G, Bressel M, Drosdowsky A, et al
    Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort.
    Oral Oncol. 2021;122:105560.
    PubMed     Abstract available


  616. MIN PARK Y, Yol Lim J, Woo Koh Y, Kim SH, et al
    Prediction of treatment outcome using MRI radiomics and machine learning in oropharyngeal cancer patients after surgical treatment.
    Oral Oncol. 2021;122:105559.
    PubMed     Abstract available


    October 2021
  617. GEORGE A, Saseendran A, Joseph ST, Gopal KR, et al
    Submandibular gland - The victim of neck dissection.
    Oral Oncol. 2021;123:105591.
    PubMed    


  618. CABEZAS-CAMARERO S, Alonso-Ovies A, Merino-Menendez S, Cabrera-Martin MN, et al
    Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer.
    Oral Oncol. 2021;123:105589.
    PubMed     Abstract available


  619. BRUIJNEN CP, de Groot LGR, Vondeling AM, de Bree R, et al
    Functional decline after surgery in older patients with head and neck cancer.
    Oral Oncol. 2021;123:105584.
    PubMed     Abstract available


  620. PUTHIYOTTIL IV, Subash A, Thakur S, Rao VUS, et al
    Elective neck dissection versus sentinel node biopsy in early oral cavity cancer - Are we ready for transition?
    Oral Oncol. 2021;123:105597.
    PubMed    


  621. SHINN JR, Carey RM, Mady LJ, Shimunov D, et al
    Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;123:105570.
    PubMed     Abstract available


  622. JOSE MARTELLI A, Assis Machado R, Medeiros Pereira W, Balduino Guimaraes Santos F, et al
    Revaluation of the treatment of head and neck cancer in Brazil during the COVID-19 pandemic - phase 2.
    Oral Oncol. 2021;123:105600.
    PubMed    


  623. YUWANATI M, Sarode SC, Gadbail A, Gondivkar S, et al
    Alcohol attributed Oral Cancer and Oral microbiome: Emerging yet neglected research domain.
    Oral Oncol. 2021;123:105596.
    PubMed    


  624. YU ST, Ge JN, Sun BH, Wei ZG, et al
    Lymph node yield in the initial central neck dissection (CND) associated with the risk of recurrence in papillary thyroid cancer: A reoperative CND cohort study.
    Oral Oncol. 2021;123:105567.
    PubMed     Abstract available


  625. SHU L, Wang D, Nannapaneni S, Sun Y, et al
    Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
    Oral Oncol. 2021;122:105546.
    PubMed     Abstract available


  626. MA D, Orner D, Ghaly MM, Parashar B, et al
    Automated health chats for symptom management of head and neck cancer patients undergoing radiation therapy.
    Oral Oncol. 2021;122:105551.
    PubMed     Abstract available


  627. ZHAO Y, Li WF, Li QJ, He SW, et al
    WIPI-1 inhibits metastasis and tumour growth via the WIPI-1-TRIM21 axis and MYC regulation in nasopharyngeal carcinoma.
    Oral Oncol. 2021;122:105576.
    PubMed     Abstract available


  628. ROSENBERG AJ, Agrawal N, Pearson A, Gooi Z, et al
    Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
    Oral Oncol. 2021;122:105566.
    PubMed     Abstract available


  629. TSENG WH, Li TH, Chiu HL, Yang TL, et al
    Long-term swallowing-related outcomes in oral cancer patients receiving proactive swallowing therapy.
    Oral Oncol. 2021;122:105569.
    PubMed     Abstract available


  630. BRIL SI, van Beers MA, Chargi N, Carrillo Minulina N, et al
    Skeletal muscle mass at C3 is a strong predictor for skeletal muscle mass at L3 in sarcopenic and non-sarcopenic patients with head and neck cancer.
    Oral Oncol. 2021;122:105558.
    PubMed    


  631. PENG H, Chen L, Mao YP, Tian L, et al
    Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma.
    Oral Oncol. 2021;122:105555.
    PubMed     Abstract available


  632. CARNEVALE C, Pagan-Pomar A, Bianchi A, Sarria-Echegaray P, et al
    Right colonic interposition for severe pharyngoesophageal stricture in head and neck patients: A feasible rescue strategy after multiple failed reconstructive options.
    Oral Oncol. 2021;121:105481.
    PubMed     Abstract available


  633. HANS S, Chebib E, Chekkoury-Idrissi Y, Distinguin L, et al
    Surgical and oncological outcomes of transoral robotic total laryngectomy: A case series.
    Oral Oncol. 2021;121:105511.
    PubMed     Abstract available


  634. FINEGERSH A, Voora RS, Panuganti B, Faraji F, et al
    Robotic surgery may improve overall survival for T1 and T2 tumors of the hypopharynx: An NCDB cohort study.
    Oral Oncol. 2021;121:105440.
    PubMed     Abstract available


  635. AL MASALMEH N, Kukreja G, Zaiem F, Raza SN, et al
    p16 positive oropharyngeal small cell cancer: A case report.
    Oral Oncol. 2021;121:105391.
    PubMed     Abstract available


  636. HARING CT, Brummel C, Bhambhani C, Jewell B, et al
    Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation.
    Oral Oncol. 2021;121:105332.
    PubMed    


    September 2021
  637. CURY SS, Miranda PM, Marchi FA, Canto LMD, et al
    Germline variants in DNA repair genes are associated with young-onset head and neck cancer.
    Oral Oncol. 2021;122:105545.
    PubMed     Abstract available


  638. WANG BC
    Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Finding the suitable population.
    Oral Oncol. 2021 Sep 28:105544. doi: 10.1016/j.oraloncology.2021.105544.
    PubMed    


  639. SARODE SC, Sarode GS, Sengupta N, Ghone U, et al
    Tobacco induced epithelial dysplasia at minor salivary gland excretory duct and oral cancer.
    Oral Oncol. 2021;122:105525.
    PubMed    


  640. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2021;122:105503.
    PubMed     Abstract available


    August 2021
  641. WRIGHT CM, Lee DY, Shimunov D, Carmona R, et al
    Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery.
    Oral Oncol. 2021;121:105509.
    PubMed     Abstract available


  642. MCDOWELL L, Corry J
    Regarding "Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey" - Intra- and inter-specialty variability and the underutilisation o
    Oral Oncol. 2021;119:105248.
    PubMed    


  643. CHOI N, Kim Z, Song BH, Park W, et al
    Prediction of risk factors for pharyngo-cutaneous fistula after total laryngectomy using artificial intelligence.
    Oral Oncol. 2021;119:105357.
    PubMed     Abstract available


    July 2021
  644. NAUTA IH, Klausch T, van de Ven PM, Hoebers FJP, et al
    The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis.
    Oral Oncol. 2021;121:105454.
    PubMed     Abstract available


  645. KIM C, Martinez E, Kulich M, Swanson MS, et al
    Surgeon practice patterns in transoral robotic surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2021;121:105460.
    PubMed     Abstract available


  646. DA COSTA REAR, da Silva Junior RG, Magalhaes LAN, Mendes JR, et al
    Locally advanced lymphoepithelial carcinoma of the larynx/hypopharynx: A case report.
    Oral Oncol. 2021;118:105373.
    PubMed     Abstract available


  647. TURNER MT, Stokes WA, Stokes CM, Hassid S, et al
    Airway and bleeding complications of transoral robotic supraglottic laryngectomy (TORS-SGL): A systematic review and meta-analysis.
    Oral Oncol. 2021;118:105301.
    PubMed    


  648. MCDOWELL L, Gough K, King M, Corry J, et al
    Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer - A review of the literature and PRO methodology.
    Oral Oncol. 2021;118:105309.
    PubMed     Abstract available


  649. DHEERAJ K, Kumar R, Pinnaka LB
    6 "I" for endoscopic surgical management of early glottic squamous cell carcinomas.
    Oral Oncol. 2021;118:105308.
    PubMed    


    June 2021
  650. DAHLSTROM KR, Anderson KS, Guo M, Kwon MC, et al
    Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial.
    Oral Oncol. 2021;120:105397.
    PubMed     Abstract available


  651. JIANG WN, Olson R
    Transoral surgery may be less cost effective than radiotherapy: In response to: Comparative cost analysis between definitive radiotherapy and transoral surgery for oropharyngeal squamous cell carcinoma: A SEER-medicare analysis.
    Oral Oncol. 2021;117:105178.
    PubMed    


  652. PARIKH AS, Kang SY
    Variation in elective treatment of the contralateral neck in oropharyngeal cancer.
    Oral Oncol. 2021;117:105186.
    PubMed    


  653. COMBES JD, Voisin N, Perie S, Malard O, et al
    History of tonsillectomy and risk of oropharyngeal cancer.
    Oral Oncol. 2021;117:105302.
    PubMed     Abstract available


  654. JANSEN F, Coupe VMH, Eerenstein SEJ, Cnossen IC, et al
    Cost-utility and cost-effectiveness of a guided self-help head and neck exercise program for patients treated with total laryngectomy: Results of a multi-center randomized controlled trial.
    Oral Oncol. 2021;117:105306.
    PubMed     Abstract available


  655. PATEL MR, Ottenstein L, Ryan M, Farrell A, et al
    TORS elective lingual tonsillectomy has less acute morbidity than therapeutic base of tongue TORS.
    Oral Oncol. 2021;117:105294.
    PubMed     Abstract available


    May 2021
  656. COSTANTINO A, De Virgilio A, Spriano G
    Is the current oropharyngeal cancer T classification adequate in the era of HPV and transoral robotic surgery?
    Oral Oncol. 2021 May 25:105359. doi: 10.1016/j.oraloncology.2021.105359.
    PubMed    


  657. ZHOU L
    Concerns about human papillomavirus-associated oropharyngeal cancer detection methods.
    Oral Oncol. 2021;116:105143.
    PubMed    


  658. LI R, Wang Q, Yan L, Zhu Y, et al
    Radiotherapy versus partial laryngectomy in the management of early glottic cancer with anterior commissure involvement: A propensity score matched study with 256 patients.
    Oral Oncol. 2021;116:105230.
    PubMed     Abstract available


    April 2021
  659. YVER CM, Shimunov D, Weinstein GS, Rajasekaran K, et al
    Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery.
    Oral Oncol. 2021;118:105307.
    PubMed     Abstract available


  660. RAJASEKARAN K, Carey RM, Lin X, Seckar TD, et al
    The microbiome of HPV-positive tonsil squamous cell carcinoma and neck metastasis.
    Oral Oncol. 2021;117:105305.
    PubMed     Abstract available


  661. KREINBRINK PJ, Li J, Parajuli S, Wise-Draper TM, et al
    Pre-treatment absolute lymphocyte count predicts for improved survival in human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;116:105245.
    PubMed     Abstract available


  662. DHAKAL R, Moeller BJ, Prabhu RS, Frenkel CH, et al
    Pattern of distant metastasis in oropharyngeal carcinoma - Do they differ by HPV status?
    Oral Oncol. 2021 Apr 18:105286. doi: 10.1016/j.oraloncology.2021.105286.
    PubMed    


  663. PRICE JM, West CM, Mistry HB, Betts G, et al
    Improved survival prediction for oropharyngeal cancer beyond TNMv8.
    Oral Oncol. 2021;115:105140.
    PubMed     Abstract available


    March 2021
  664. DE ALMEIDA JR, Seungyeon Kim V, O'Sullivan B, Goldstein DP, et al
    Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey.
    Oral Oncol. 2021;114:105165.
    PubMed     Abstract available


  665. FERRARI M, Migliorati S, Tomasoni M, Crisafulli V, et al
    Sinonasal cancer encroaching the orbit: Ablation or preservation?
    Oral Oncol. 2021;114:105185.
    PubMed     Abstract available


  666. YANG K, Ahn YC, Nam H, Hong SD, et al
    Clinical features of post-radiation nasopharyngeal necrosis and their outcomes following surgical intervention in nasopharyngeal cancer patients.
    Oral Oncol. 2021;114:105180.
    PubMed     Abstract available


  667. HENG Y, Zhang D, Zhou L, Zhang M, et al
    Assessment and treatment strategies for occult contralateral lymph node metastasis in hypopharyngeal squamous cell carcinoma patients with ipsilateral node-positive necks.
    Oral Oncol. 2021;114:105183.
    PubMed     Abstract available


  668. CUI J, Wang D, Nie D, Liu W, et al
    Difference in tumor mutation burden between squamous cell carcinoma in the oral cavity and larynx.
    Oral Oncol. 2021;114:105142.
    PubMed     Abstract available


  669. OPPELT P, Ley JC, Worden F, Palka K, et al
    Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.
    Oral Oncol. 2021;114:105164.
    PubMed     Abstract available


  670. GOOSMANN M, Chang S, Craig J
    Treating sinonasal crusting and infection after palatal and sinonasal cancer resection with topical antibiotic irrigations.
    Oral Oncol. 2021;114:105077.
    PubMed    


    February 2021
  671. FADEN DL, O'Boyle CJ, Lin DT, Deschler DG, et al
    Prospective assessment of multiple HPV-positive oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2021 Feb 15:105212. doi: 10.1016/j.oraloncology.2021.105212.
    PubMed    


  672. LEE SJ, Kim YS, Kay CS, Kim M, et al
    The effect of adjuvant chemotherapy and early tumor regression on the outcome of nasopharyngeal cancer patients treated with concurrent chemoradiotherapy.
    Oral Oncol. 2021;113:105130.
    PubMed     Abstract available


  673. CARNEVALE C, Ortiz-Gonzalez I, Ortiz-Gonzalez A, Bodi-Blanes L, et al
    Early T1-T2 stage p16+ oropharyngeal tumours. Role of upfront transoral robotic surgery in de-escalation treatment strategies. A review of the current literature.
    Oral Oncol. 2021;113:105111.
    PubMed     Abstract available


  674. HEFT NEAL ME, Gao RW, Brennan JR, Haring CT, et al
    Functional outcomes and tracheostomy dependence following salvage oropharyngeal surgery.
    Oral Oncol. 2021;113:105034.
    PubMed    


    January 2021
  675. PILAR A, Yu E, Su J, O'Sullivan B, et al
    Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma.
    Oral Oncol. 2021;114:105167.
    PubMed     Abstract available


  676. BHATTASALI O, Torres FA, Kang HK, Thompson LDR, et al
    Prognostic impact of retropharyngeal lymphadenopathy in early-stage HPV-associated oropharyngeal cancer: Implications for staging optimization.
    Oral Oncol. 2021;114:105147.
    PubMed    


    December 2020
  677. CHRISTOPHERSON KM, Moreno AC, Elgohari B, Gross N, et al
    Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation.
    Oral Oncol. 2020;113:105125.
    PubMed     Abstract available


    September 2020
  678. MARTIN M, Sautois B
    Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene.
    Oral Oncol. 2020 Sep 1:104989. doi: 10.1016/j.oraloncology.2020.104989.
    PubMed    


    August 2020
  679. CHEN TC, Wu CT, Wang CP, Lou PJ, et al
    The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Oral Oncol. 2020;111:104945.
    PubMed     Abstract available


  680. WANG J, Lian CL, Zheng H, Lin LE, et al
    Cognitive dysfunction in patients with nasopharyngeal carcinoma after induction chemotherapy.
    Oral Oncol. 2020;111:104921.
    PubMed     Abstract available


    July 2020
  681. ZENG YY, Xiang ZZ, He T, Liu F, et al
    The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;111:104924.
    PubMed     Abstract available


  682. WANG Q, Xu G, Xia Y, Zuo J, et al
    Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;111:104925.
    PubMed     Abstract available


  683. LI W, Lu H, Liu J, Liu Q, et al
    A novel nomogram to predict survival in patients with recurrent nasopharyngeal carcinoma after salvage endoscopic surgery.
    Oral Oncol. 2020;111:104922.
    PubMed     Abstract available


  684. HSU AC, Kokot NC, Eisenberg BL, Thomas JS, et al
    Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.
    Oral Oncol. 2020 Jul 11:104899. doi: 10.1016/j.oraloncology.2020.104899.
    PubMed     Abstract available


  685. MATOS LL, Pinheiro RA, Kowalski LP
    Depth of invasion applied to oropharynx does not improve prognosis discrimination according to AJCC stage groups for oral cancer.
    Oral Oncol. 2020 Jul 9:104890. doi: 10.1016/j.oraloncology.2020.104890.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.